




INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C07D 239/50, 239/48, 239/46, 239/42, 401/12, A61K 31/505		A1	(11) International Publication Number: WO 99/50250 (43) International Publication Date: 7 October 1999 (07.10.99)
(21) International Application Number: PCT/EP99/02043			B-2300 Turnhout (BE). KUKLA, Michael, Joseph [US/US]; 1551 Oak Hollow Drive, Maple Glen, PA 19002 (US). LUDOVICI, Donald, William [US/US]; 1390 Masi Road, Quakertown, PA 18951 (US). VAN AKEN, Koen, Jeanne, Alfons [BE/BE]; Tuinbouwstraat 22, bus 2, B-2300 Turnhout (BE).
(22) International Filing Date: 24 March 1999 (24.03.99)			(74) Common Representative: JANSSEN PHARMACEUTICA N.V. ; Att. Frank Daelemans, Patent Dept., Turnhoutseweg 30, B-2340 Beerse (BE).
(30) Priority Data: 60/079,632 27 March 1998 (27.03.98) US 98201587.7 14 May 1998 (14.05.98) EP 98203948.9 25 November 1998 (25.11.98) EP			(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TI, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).
(71) Applicant (for all designated States except US): JANSSEN PHARMACEUTICA N.V. [BE/BE]; Turnhoutseweg 30, B-2340 Beerse (BE).			
(72) Inventors; and (75) Inventors/Applicants (for US only): ANDRIES, Koenraad, Jozef, Lodewijk, Marcel [BE/BE]; Oosteneinde 9, B-2340 Beerse (BE). DE CORTE, Bart [BE/US]; 1590 Winding Road, Southampton, PA 18966 (US). DE JONGE, Marc, René [NL/NL]; Hontenissestraat 3, NL-5045 CA Tilburg (NL). HEERES, Jan [NL/BE]; Leemkuilen 18, B-2350 Vosselaar (BE). HO, Chih, Yung [US/US]; 600 Drinon Way, Lansdale, PA 19446 (US). JANSSEN, Marcel, August, Constant [BE/BE]; Karel Druytelaan 15, B-2350 Vosselaar (BE). JANSSEN, Paul, Adriaan, Jan [BE/BE]; Antwerpsesteenweg 20, B-2350 Vosselaar (BE). KOYMANS, Lucien, Maria, Henricus [NL/BE]; Stationstraat 68 bus 4,			Published With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.
(54) Title: HIV INHIBITING PYRIMIDINE DERIVATIVES			
(57) Abstract			
<p>This invention concerns the use of the compounds of formula (I), the <i>N</i>-oxides, the pharmaceutically acceptable addition salts and the stereochemically isomeric forms thereof, wherein A is CH, CR⁴ or N; n is 0 to 4; Q is hydrogen or -NR¹R²; R¹ and R² are selected from hydrogen, hydroxy, C₁₋₁₂alkyl, C₁₋₁₂alkyloxy, C₁₋₁₂alkylcarbonyl, C₁₋₁₂alkyloxycarbonyl, aryl, amino, mono- or di(C₁₋₁₂alkyl)- amino, mono- or di(C₁₋₁₂alkyl)aminocarbonyl wherein each C₁₋₁₂alkyl may optionally be substituted; or R¹ and R² taken together may form pyrrolidinyl, piperidinyl, morpholinyl, azido or mono- or di(C₁₋₁₂alkyl)aminoC₁₋₄alkylidene; R³ is hydrogen, aryl, C₁₋₆alkylcarbonyl, optionally substituted C₁₋₆alkyl, C₁₋₆alkyloxy carbonyl; and R⁴ is hydroxy, halo, optionally substituted C₁₋₆alkyl, C₁₋₆alkyloxy, cyano, aminocarbonyl, nitro, amino, trihalomethyl, trihalomethoxy; R⁵ is hydrogen or C₁₋₄alkyl; L is optionally substituted C₁₋₁₀alkyl, C₃₋₁₀alkenyl, C₃₋₁₀alkynyl, C₃₋₇cycloalkyl; or L is -X¹R⁶ or -X²-Alk-R⁷ wherein R⁶ and R⁷ are optionally substituted phenyl; X¹ and X² are -NR³-, -NH-NH-, -N=N-, -O-, -S-, -S(=O)- or -S(=O)₂-; Alk is C₁₋₄alkanediyl; aryl is optionally substituted phenyl; Het is an optionally substituted aliphatic or aromatic heterocyclic radical; for the manufacture of a medicine for the treatment of subjects suffering from HIV (Human Immunodeficiency Virus) infection. It further relates to new compounds being a subgroup of the compounds of formula (I), their preparation and compositions comprising them.</p>			
 (1)			

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon	KR	Republic of Korea	PL	Poland		
CN	China	KZ	Kazakhstan	PT	Portugal		
CU	Cuba	LC	Saint Lucia	RO	Romania		
CZ	Czech Republic	LI	Liechtenstein	RU	Russian Federation		
DE	Germany	LK	Sri Lanka	SD	Sudan		
DK	Denmark	LR	Liberia	SE	Sweden		
EE	Estonia			SG	Singapore		

-1-

HIV INHIBITING PYRIMIDINE DERIVATIVES

5 The present invention is concerned with pyrimidine derivatives having HIV replication inhibiting properties. The invention further relates to methods for their preparation and pharmaceutical compositions comprising them. The invention also relates to the use of said compounds in the manufacture of a medicament useful for the treatment of subjects suffering from HIV (Human Immunodeficiency Virus) infection.

10 Compounds structurally related to the present compounds are disclosed in the prior art.


JP-2,052,360, JP-2,308,248, JP-9,080,676 and JP-9,068,784 disclose a number of trisubstituted pyrimidines useful in photographic material. JP-8,199,163 discloses trisubstituted pyrimidines useful in an organic electroluminescent device. JP-2,300,264 15 and GB-1,477,349 disclose pyrimidinetriamines for their use in the dye industry.

20 J. Indian Chem. Soc. (1975), 52(8), 774-775 discloses the synthesis of some bis(arylarnino)pyrimidines. J. Heterocycl. Chem. (1973), 10(2), 167-171 discloses the condensation of various aminopyrimidines with picryl halides. J. Org. Chem. (1961), 26, 4433-4440 discloses several triaminopyrimidines as intermediates in the synthesis of triazolo[4,5-d]pyrimidines.

WO 91/18887 discloses diaminopyrimidines as gastric acid secretion inhibitors.

25 Unexpectedly, it has now been found that the compounds of formula (I) effectively inhibit the replication of the Human Immunodeficiency Virus (HIV) and consequently may be useful for the treatment of individuals infected by HIV.

The present invention concerns the use of the compounds of formula



30 the *N*-oxides, the pharmaceutically acceptable addition salts and the stereochemically isomeric forms thereof, wherein
 A is CH, CR⁴ or N;
 n is 0, 1, 2, 3 or 4;
 35 Q is hydrogen or -NR¹R²;

R¹ and R² are each independently selected from hydrogen, hydroxy, C₁₋₁₂alkyl, C₁₋₁₂alkyloxy, C₁₋₁₂alkylcarbonyl, C₁₋₁₂alkyloxycarbonyl, aryl, amino, mono- or di(C₁₋₁₂alkyl)amino, mono- or di(C₁₋₁₂alkyl)aminocarbonyl wherein each of the aforementioned C₁₋₁₂alkyl groups may optionally and each individually be substituted with one or two substituents each independently selected from hydroxy, C₁₋₆alkyloxy, hydroxyC₁₋₆alkyloxy, carboxyl, C₁₋₆alkyloxycarbonyl, cyano, amino, imino, aminocarbonyl, aminocarbonylamino, mono- or di(C₁₋₆alkyl)amino, aryl and Het; or

5 R¹ and R² taken together may form pyrrolidinyl, piperidinyl, morpholinyl, azido or mono- or di(C₁₋₁₂alkyl)aminoC₁₋₄alkylidene;

10 R³ is hydrogen, aryl, C₁₋₆alkylcarbonyl, C₁₋₆alkyl, C₁₋₆alkyloxycarbonyl, C₁₋₆alkyl substituted with C₁₋₆alkyloxycarbonyl; and each R⁴ independently is hydroxy, halo, C₁₋₆alkyl, C₁₋₆alkyloxy, cyano, amino- carbonyl, nitro, amino, trihalomethyl, trihalomethoxy or C₁₋₆alkyl substituted with

15 cyano or aminocarbonyl;

R⁵ is hydrogen or C₁₋₄alkyl;

16 L is C₁₋₁₀alkyl, C₃₋₁₀alkenyl, C₃₋₁₀alkynyl, C₃₋₇cycloalkyl, or C₁₋₁₀alkyl substituted with one or two substituents independently selected from C₃₋₇cycloalkyl, indanyl, indolyl and phenyl, wherein said phenyl, indanyl and indolyl may be substituted with one, two, three, four or where possible five substituents each independently selected from halo, hydroxy, C₁₋₆alkyl, C₁₋₆alkyloxy, cyano, aminocarbonyl, C₁₋₆alkyloxycarbonyl, formyl, nitro, amino, trihalomethyl, trihalomethoxy and C₁₋₆alkylcarbonyl; or

20 L is -X¹-R⁶ or -X²-Alk-R⁷ wherein

25 R⁶ and R⁷ each independently are phenyl or phenyl substituted with one, two, three, four or five substituents each independently selected from halo, hydroxy, C₁₋₆alkyl, C₁₋₆alkyloxy, C₁₋₆alkylcarbonyl, C₁₋₆alkyloxycarbonyl, formyl, cyano, aminocarbonyl, nitro, amino, trihalomethoxy and trihalomethyl; and X¹ and X² are each independently -NR³-, -NH-NH-, -N=N-, -O-, -S-, -S(=O)- or -S(=O)₂;

30 Alk is C₁₋₄alkanediyl;

aryl is phenyl or phenyl substituted with one, two, three, four or five substituents each independently selected from halo, C₁₋₆alkyl, C₁₋₆alkyloxy, cyano, nitro and trifluoromethyl;

35 Het is an aliphatic or aromatic heterocyclic radical; said aliphatic heterocyclic radical is selected from pyrrolidinyl, piperidinyl, homopiperidinyl, piperazinyl, morpholinyl, tetrahydrofuranyl and tetrahydrothienyl wherein each of said aliphatic heterocyclic radical may optionally be substituted with an oxo group; and said aromatic hetero-


cyclic radical is selected from pyrrolyl, furanyl, thienyl, pyridyl, pyrimidinyl, pyrazinyl and pyridazinyl wherein each of said aromatic heterocyclic radical may optionally be substituted with hydroxy;

for the manufacture of a medicine for the treatment of subjects suffering from HIV

5 (Human Immunodeficiency Virus) infection.

The present invention also relates to a method of treating warm-blooded animals suffering from HIV (Human Immunodeficiency Virus) infection. Said method comprises the administration of a therapeutically effective amount of a compound of 10 formula (I) or any subgroup thereof, a *N*-oxide form, a pharmaceutically acceptable addition salt or a stereochemically isomeric form thereof in admixture with a pharmaceutical carrier.

This invention also concerns compounds of formula



15

the *N*-oxides, the pharmaceutically acceptable addition salts and the stereochemically isomeric forms thereof, wherein L, Q, R³, R⁴, R⁵ and A are as defined under formula (I), and

R⁴' is halo, C₁₋₆alkyl, cyano, aminocarbonyl, nitro, trihalomethyl, trihalomethoxy or

20 C₁₋₆alkyl substituted with cyano or aminocarbonyl;

n' is 0, 1, 2 or 3;

with the proviso that Q and L are other than anilino, 2,4,6-trinitro-anilino, 3-methoxy-anilino, 4-methoxy-anilino, 3,4-dimethoxy-anilino, 3-chloro-4-fluoro-anilino, 4-cyano-anilino, 2-(C₁₋₆alkyl)-anilino, 4-(C₁₋₆alkyl)-anilino, 3-chloro-anilino, 4-bromo-anilino, 25 4-nitro-anilino and 4-chloro-anilino.

As used in the foregoing definitions and hereinafter halo defines fluoro, chloro, bromo and iodo; C₁₋₄alkyl as a group or part of a group encompasses the straight and branched chained saturated hydrocarbon radicals having from 1 to 4 carbon atoms such as, for 30 example, methyl, ethyl, propyl, butyl and the like; C₁₋₆alkyl as a group or part of a group encompasses the straight and branched chained saturated hydrocarbon radicals as defined in C₁₋₄alkyl as well as the higher homologues thereof containing 5 or 6 carbon atoms such as, for example pentyl or hexyl; C₁₋₁₀alkyl as a group or part of a group

group encompasses the straight and branched chained saturated hydrocarbon radicals as defined in C₁-6alkyl as well as the higher homologues thereof containing 7 to 10 carbon atoms such as, for example, heptyl, octyl, nonyl or decyl; C₁-12alkyl as a group or part of a group encompasses the straight and branched chained saturated hydrocarbon

5 radicals as defined in C₁-10alkyl as well as the higher homologues thereof containing 11 or 12 carbon atoms such as, for example, undecyl, dodecyl and the like; C₁-4alkylidene as a group or part of a group defines bivalent straight and branched chained hydrocarbons having from 1 to 4 carbon atoms such as, for example, methylene, ethylidene, propylidene, butylidene and the like; C₁-4alkanediyl as a group


10 or part of a group encompasses those radicals defined under C₁-4alkylidene as well as other bivalent straight and branched chained hydrocarbons having from 1 to 4 carbon atoms such as, for example, 1,2-ethanediyl, 1,3-propanediyl, 1,4-butanediyl and the like; C₃-7cycloalkyl as a group or part of a group is generic to cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and cycloheptyl; C₃-10alkenyl as a group or part of a group

15 defines straight and branch chained hydrocarbon radicals containing one double bond and having from 3 to 10 carbon atoms such as, for example, 2-propenyl, 2-butenyl, 2-pentenyl, 3-pentenyl, 3-methyl-2-but enyl, 3-hexenyl, 3-heptenyl, 2-octenyl, 2-nonenyl, 2-decenyl and the like, whereby the carbon atom attached to the pyrimidine ring is preferably an aliphatic carbon atom; C₃-10alkynyl as a group or part of a group

20 defines straight and branch chained hydrocarbon radicals containing one triple bond and having from 3 to 10 carbon atoms such as, for example, 2-propynyl, 2-butynyl, 2-pentynyl, 3-pentynyl, 3-methyl-2-butynyl, 3-hexynyl, 3-heptynyl, 2-octynyl, 2-nonyn yl, 2-decynyl and the like, whereby the carbon atom attached to the pyrimidine ring is preferably an aliphatic carbon atom.


25

It is to be understood that the three substituents [L, Q and NR³(optionally substituted phenyl or pyridyl)] on the pyrimidine ring can be on any free position of the pyrimidine ring. Thus, given the following numbering of the pyrimidine ring




30 the three substituents may be connected to the pyrimidine ring in three different ways : 2-L, 4-Q, 6-NR³(optionally substituted phenyl or pyridyl); or 4-L, 2-Q, 6-NR³(optionally substituted phenyl or pyridyl); or 6-L, 4-Q, 2-NR³(optionally substituted phenyl or pyridyl).

The positions 4 and 6 are equivalent to one another. For instance, substitution pattern 6-L, 4-Q, 2-NR³(optionally substituted phenyl or pyridyl), which is a preferred substitution pattern, is equivalent to substitution pattern 4-L, 6-Q, 2-NR³(optionally substituted phenyl or pyridyl). Said subgroup of compounds is represented by formula



5

An interesting group of compounds are the compounds of formula



Of particular interest are those compounds of formula (I'-1) wherein L and Q are other than anilino, 2,4,6-trinitro-anilino, 4-(C₁-6alkyl)-anilino, 4-bromo-anilino, 4-nitro-

10 anilino and 4-chloro-anilino; and of more particular interest are those compounds of formula (I'-1) wherein R⁴ is cyano, aminocarbonyl or C₁-6alkyl substituted with cyano or aminocarbonyl.

15 The addition salts as mentioned herein are meant to comprise the therapeutically active addition salt forms which the compounds of the present invention are able to form with appropriate acids, such as, for example, inorganic acids such as hydrohalic acids, e.g. hydrochloric or hydrobromic acid; sulfuric; nitric; phosphoric and the like acids; or organic acids such as, for example, acetic, propanoic, hydroxyacetic, lactic, pyruvic, oxalic, malonic, succinic, maleic, fumaric, malic, tartaric, citric, methanesulfonic, 20 ethanesulfonic, benzenesulfonic, *p*-toluenesulfonic, cyclamic, salicylic, *p*-amino-salicylic, pamoic and the like acids.

The pharmaceutically acceptable addition salts as mentioned hereinabove are also meant to comprise the therapeutically active non-toxic base, in particular, a metal or amine addition salt forms which the compounds of the present invention are able to form. Said salts can conveniently be obtained by treating the compounds of the present invention containing acidic hydrogen atoms with appropriate organic and inorganic bases such as, for example, the ammonium salts, the alkali and earth alkaline metal salts, e.g. the lithium, sodium, potassium, magnesium, calcium salts and the like, salts

with organic bases, e.g. the benzathine, *N*-methyl-D-glucamine, hydrabamine salts, and salts with amino acids such as, for example, arginine, lysine and the like.

Conversely said salt forms can be converted by treatment with an appropriate base or acid into the free acid or base form.

5

The term addition salts also comprises the hydrates and the solvent addition forms which the compounds of the present invention are able to form. Examples of such forms are e.g. hydrates, alcoholates and the like.

10 The term stereochemically isomeric forms of compounds of the present invention, as used hereinbefore, defines all possible compounds made up of the same atoms bonded by the same sequence of bonds but having different three-dimensional structures which are not interchangeable, which the compounds of the present invention may possess. Unless otherwise mentioned or indicated, the chemical designation of a compound
15 encompasses the mixture of all possible stereochemically isomeric forms which said compound may possess. Said mixture may contain all diastereomers and/or enantiomers of the basic molecular structure of said compound. All stereochemically isomeric forms of the compounds of the present invention both in pure form or in admixture with each other are intended to be embraced within the scope of the present
20 invention.

Some of the compounds of the present invention may also exist in their tautomeric forms. Such forms although not explicitly indicated in the above formula are intended to be included within the scope of the present invention.

25

Whenever used hereinafter, the term "compounds of the present invention" is meant to include the compounds of formula (I), (I-1), (I'), (I'-1) or any subgroup thereof, also the *N*-oxides, the pharmaceutically acceptable addition salts and all stereoisomeric forms.

30 The group containing those compounds of the present invention wherein Q is NR¹R², each R⁴ independently is hydroxy, halo, C₁₋₆alkyl, C₁₋₆alkyloxy, cyano, amino-carbonyl, nitro, amino, trihalomethyl or trihalomethoxy ; L is C₁₋₁₀alkyl, C₃₋₁₀alkenyl, C₃₋₁₀alkynyl, C₃₋₇cycloalkyl, or C₁₋₁₀alkyl substituted with one or two substituents independently selected from C₃₋₇cycloalkyl, indolyl or indolyl substituted with one,
35 two, three or four substituents each independently selected from halo, C₁₋₆alkyl, C₁₋₆alkyloxy, cyano, aminocarbonyl, nitro, amino, trihalomethyl, trihalomethoxy and C₁₋₆alkylcarbonyl, phenyl or phenyl substituted with one, two, three, four or five substituents each independently selected from halo, hydroxy, C₁₋₆alkyl, C₁₋₆alkyloxy,

cyano, aminocarbonyl, nitro, amino, trihalomethyl, trihalomethoxy and C₁-6alkylcarbonyl; or L is -X¹-R⁶ wherein R⁶ is phenyl or phenyl substituted with one, two, three, four or five substituents each independently selected from halo, C₁-6alkyl, C₁-6alkyloxy, C₁-6alkylcarbonyl, cyano, nitro and trifluoromethyl; is of interest.

5

Also of interest is the group containing those compounds of the present invention wherein Q is NR¹R²; each R⁴ independently is hydroxy, halo, C₁-6alkyl, C₁-6alkyloxy, cyano, aminocarbonyl, nitro, amino, trihalomethyl or trihalomethoxy ; L is C₁-10alkyl substituted with one or two substituents independently selected from phenyl or phenyl substituted with one, two, three, four or five substituents each independently selected from halo, hydroxy, C₁-6alkyl, C₁-6alkyloxy, cyano, aminocarbonyl, nitro, amino, trihalomethyl, trihalomethoxy and C₁-6alkylcarbonyl; or L is -X¹-R⁶ wherein R⁶ is phenyl or phenyl substituted with one, two, three, four or five substituents each independently selected from halo, C₁-6alkyl, C₁-6alkyloxy, C₁-6alkylcarbonyl, cyano, nitro and trifluoromethyl; with the proviso that compounds

- (a) *N*²-hydroxy-*N*²-methyl-*N*⁴,*N*⁶-diphenyl-2,4,6-pyrimidinetriamine;
- (b) *N*,*N*,*N*',*N*',*N*"',*N*"-hexakis(3-methylphenyl)-2,4,6-pyrimidinetriamine;
- (c) *N*⁴-methyl-*N*²-(2-methylphenyl)-*N*⁴-phenyl-2,4,6-pyrimidinetriamine;
- (d) *N*⁴-methyl-*N*²-(2-methylphenyl)-*N*⁴-phenyl-6-(phenylmethyl)-2,4-pyrimidine diamine;
- (e) *N*⁴-(2-methylphenyl)-6-(phenylmethyl)-2,4-pyrimidinediamine;
- (f) *N*,*N*',*N*"-tris(4-methoxyphenyl)-2,4,6-pyrimidinetriamine;
- (g) *N*,*N*-bis(4-hexylphenyl)-6-(4-methoxyphenoxy)-2,4-pyrimidinediamine;
- (h) *N*²,*N*⁴-bis(4-hexylphenyl)-*N*⁶,*N*⁶-dimethyl-2,4,6-pyrimidinetriamine;
- (i) *N*,*N*',*N*"-tris(4-hexylphenyl)-2,4,6-pyrimidinetriamine;
- (j) *N*²,*N*²-dimethyl-*N*⁴,*N*⁶-bis(4-methylphenyl)-2,4,6-pyrimidinetriamine;
- (k) *N*,*N*',*N*"-tris(4-methylphenyl)-2,4,6-pyrimidinetriamine;
- (l) *N*,*N*',*N*"-triphenyl-2,4,6-pyrimidinetriamine;
- (m) *N*,*N*',*N*',*N*',*N*"',*N*"-hexakis(4-ethoxyphenyl)-2,4,6-pyrimidinetriamine;
- (n) *N*⁴,*N*⁶-bis(2-chlorophenyl)-2,4,6-pyrimidinetriamine;
- (o) *N*⁴,*N*⁶-bis(3-chlorophenyl)-2,4,6-pyrimidinetriamine;
- (p) *N*⁴,*N*⁶-bis(2-ethoxyphenyl)-2,4,6-pyrimidinetriamine;
- (q) *N*⁴,*N*⁶-bis(4-ethoxyphenyl)-2,4,6-pyrimidinetriamine;
- (r) *N*⁴,*N*⁶-bis(2-methylphenyl)-2,4,6-pyrimidinetriamine;
- (s) *N*⁴,*N*⁶-bis(4-bromophenyl)-2,4,6-pyrimidinetriamine;
- (t) *N*⁴,*N*⁶-bis(4-methylphenyl)-2,4,6-pyrimidinetriamine;
- (u) *N*²,*N*⁴-bis(4-methoxyphenyl)-2,4,6-pyrimidinetriamine;

- (v) $N2,N4$ -bis(4-methylphenyl)-2,4,6-pyrimidinetriamine;
- (w) N,N',N'' -tris(2,4,6-trinitrophenyl)-2,4,6-pyrimidinetriamine;
- (x) $N4,N6$ -bis(4-chlorophenyl)-2,4,6-pyrimidinetriamine;
- (y) $N4,N6$ -bis(4-methoxyphenyl)-2,4,6-pyrimidinetriamine;
- 5 (z) $N2,N4,N6$ -trimethyl- $N2,N4,N6$ -triphenyl pyrimidine-2,4,6-triyltriamine;
- (aa) $N4,N4$ -dimethyl- $N2,N6$ -di-*p*-tolyl-pyrimidine-2,4,6-triyltriamine; and
- (bb) $N2,N4$ -diphenyl-pyrimidine-2,4,6-triyltriamine are not included.

10 Suitably, Q may also be hydrogen in the above two groups of interest.

15 A special group of compounds are those compounds of formula (I) or (I') wherein n is at least 1 and at least one R^4 is cyano; preferably, n is 1 and R^4 is cyano substituted in the para position relative to the NR^3 moiety.

20 Another special group of compounds contains those compounds of formula (I) or (I') which are other than

- (c) $N4$ -methyl- $N2$ -(2-methylphenyl)- $N4$ -phenyl-2,4,6-pyrimidinetriamine;
- (d) $N4$ -methyl- $N2$ -(2-methylphenyl)- $N4$ -phenyl-6-(phenylmethyl)-2,4-pyrimidine-diamine;
- 25 (e) $N4$ -(2-methylphenyl)-6-(phenylmethyl)-2,4-pyrimidinediamine; the *N*-oxides, the pharmaceutically acceptable addition salts and the stereochemically isomeric forms thereof.

30 An interesting group of compounds are those compounds of the present invention wherein the NR^3 (substituted phenyl or pyridyl) moiety is in the 4- or 6-position of the pyrimidine ring.

35 Another interesting group are those compounds of the present invention wherein each R^4 independently is hydroxy, halo, C_{1-6} alkyloxy, cyano, aminocarbonyl, nitro, amino, trihalomethyl or trihalomethoxy; R^6 is phenyl or phenyl substituted with one, two or three, four or five substituents each independently selected from halo, C_{1-6} alkyloxy, C_{1-6} alkylcarbonyl, cyano, nitro and trifluoromethyl; and aryl is phenyl or phenyl substituted with one, two, three, four or five substituents each independently selected from halo, C_{1-6} alkyloxy, cyano, nitro and trifluoromethyl.

40 Suitably, Q is NR^1R^2 wherein R^1 is hydrogen, hydroxy, C_{1-12} alkyl, C_{1-12} alkyloxy, C_{1-12} alkylcarbonyl, C_{1-12} alkyloxycarbonyl, aryl, amino, mono- or di(C_{1-12} alkyl)amino, mono- or di(C_{1-12} alkyl)aminocarbonyl; and R^2 is hydroxy, C_{1-12} alkyl, C_{1-12} alkyloxy, C_{1-12} alkylcarbonyl, C_{1-12} alkyloxycarbonyl, aryl, amino, mono- or di(C_{1-12} alkyl)amino,

mono- or di(C₁₋₁₂alkyl)aminocarbonyl; wherein each of the aforementioned C₁₋₁₂alkyl groups may optionally and each individually be substituted with one or two substituents each independently selected from hydroxy, C₁₋₆alkyloxy, hydroxyC₁₋₆alkyloxy, carboxyl, C₁₋₆alkyloxycarbonyl, cyano, amino, imino, aminocarbonyl, aminocarbonyl-
5 amino, mono- or di(C₁₋₆alkyl)amino, aryl and Het; or R¹ and R² taken together may form pyrrolidinyl, piperidinyl, morpholinyl, azido or mono- or di(C₁₋₁₂alkyl)amino-C₁₋₄alkylidene.

Suitably, L is C₁₋₁₀alkyl substituted with one or two substituents independently selected
10 from C₃₋₇cycloalkyl, indanyl, indolyl and phenyl, wherein said phenyl, indanyl and indolyl may be substituted with one, two, three, four or where possible five substituents each independently selected from halo, hydroxy, C₁₋₆alkyl, C₁₋₆alkyloxy, cyano, aminocarbonyl, C₁₋₆alkyloxycarbonyl, formyl, nitro, amino, trihalomethyl, trihalo-
15 methyloxy and C₁₋₆alkylcarbonyl; or L is -X¹-R⁶ or -X²-Alk-R⁷ and when X¹ is NR³, then R⁶ is phenyl substituted with one, two, three, four or five substituents each independently selected from C₁₋₆alkyloxycarbonyl, formyl, nitro and trihalomethyloxy.
15

Suitably, R⁴ or R^{4'} is nitro, trihalomethyloxy or C₁₋₆alkyl substituted with cyano or aminocarbonyl.

20 Suitably, R⁶ is phenyl or phenyl substituted with one, two, three, four or five substituents each independently selected from halo, hydroxy, C₁₋₆alkyl, C₁₋₆alkyloxy, C₁₋₆alkyloxycarbonyl, formyl, cyano, aminocarbonyl, nitro, amino, trihalomethyloxy and trihalomethyl.
25

Suitably, both Q and R⁵ are hydrogen.

Suitably, L is C₁₋₁₀alkyl substituted with one or two substituents independently selected
30 from C₃₋₇cycloalkyl, indanyl, indolyl and phenyl, wherein said phenyl, indanyl and indolyl may be substituted with one, two, three, four or where possible five substituents each independently selected from halo, hydroxy, C₁₋₆alkyl, C₁₋₆alkyloxy, cyano, aminocarbonyl, C₁₋₆alkyloxycarbonyl, formyl, nitro, amino, trihalomethyl, trihalo-
methyloxy and C₁₋₆alkylcarbonyl; or L is -X¹-R⁶ or -X²-Alk-R⁷; and R⁵ is hydrogen.

35 Particular groups of compounds are those groups wherein one or more of the following conditions are met :
(i) n is 0, 1, 2 or 3;
(ii) Q is hydrogen;

5 (iii) Q is NR¹R² wherein R¹ and R² are each independently selected from hydrogen, hydroxy, C₁₋₁₂alkyl, C₁₋₁₂alkyloxy, C₁₋₁₂alkylcarbonyl, C₁₋₁₂alkyloxycarbonyl, cyano wherein the aforementioned C₁₋₁₂alkyl groups may optionally and each individually be substituted with one or two substituents each independently selected from hydroxy, cyano, C₁₋₆alkyloxy, hydroxyC₁₋₆alkyloxy, aryl and Het; or R¹ and R² taken together may form mono- or di(C₁₋₁₂alkyl)aminoC₁₋₄alkylidene;

10 (iv) R³ is hydrogen or C₁₋₆alkyl;

(v) R⁴ is cyano, aminocarbonyl, amino, nitro, hydroxy, halo, C₁₋₆alkyl or cyanoC₁₋₆alkyl;

15 (vi) R⁴ is cyano, aminocarbonyl, halo, C₁₋₆alkyl or cyanoC₁₋₆alkyl;

(vii) R⁵ is hydrogen or methyl;

(viii) L is C₁₋₁₀alkyl substituted with phenyl substituted with one or two halogens; or L is -X¹-R⁶ wherein R⁶ is phenyl substituted with one, two or three substituents selected from C₁₋₆alkyl, trifluoromethyl, trifluoromethoxy, cyano, and halogen, and X¹ is -S-, -O- or -NR³-; or L is -X²-Alk-R⁷ wherein R⁷ is phenyl substituted with one, two or three substituents selected from C₁₋₆alkyl, cyano, and halogen and X² is NH.

20 Other particular compounds are those compounds of the present invention wherein L contains phenyl, 2,6-disubstituted-phenyl, 2,4,6-trisubstituted-phenyl or 2,3,4,5-tetra-substituted-phenyl; especially, L contains phenyl, 2,4,6-trihalo-phenyl, 2,4,6-triC₁₋₄alkyl-phenyl, 2,3,4,5-tetrahalo-phenyl, 2,4-dihalo-6-C₁₋₄alkyl-phenyl, 2,6-dihalo-4-C₁₋₄alkyl-phenyl, 2,6-dihalo-4-cyano-phenyl, 2,6-dihalo-4-trifluoromethoxy-phenyl, 2,6-dihalo-4-trifluoromethyl-phenyl, 2,6-diC₁₋₄alkyl-4-halo-phenyl, 2,6-diC₁₋₄alkyl-4-cyano-phenyl, 2,6-dihalo-phenyl or 2,6-diC₁₋₄alkyl-phenyl; more in particular, L contains phenyl, 2,4,6-trichloro-phenyl, 2,4,6-trimethyl-phenyl, 2,4-dibromo-3,5-dichloro-phenyl, 2,4-dibromo-6-fluoro-phenyl, 2,4-dichloro-6-methyl-phenyl, 2,6-dibromo-4-isopropyl-phenyl, 2,6-dibromo-4-methyl-phenyl, 2,6-dibromo-4-prop-1-yl-phenyl, 2,6-dichloro-4-cyano-phenyl, 2,6-dichloro-4-trifluoromethoxy-phenyl, 2,6-dichloro-4-trifluoromethyl-phenyl, 2,6-dichloro-phenyl, 2,6-dimethyl-4-(1,1-dimethylethyl)-phenyl, 2,6-dimethyl-phenyl, 2-bromo-4-fluoro-6-methyl-phenyl, 2-bromo-6-chloro-4-fluoro-phenyl, 4-bromo-2,6-dimethyl-phenyl, 4-chloro-2,6-dimethyl-phenyl, or 4-cyano-2,6-dimethyl-phenyl.

35

More particular compounds are the compounds of the present invention wherein L is 2,6-dichlorobenzyl, or L is -X¹-R⁶ wherein X¹ is -NR³-, -S- or -O- and R⁶ is 2,4,6-tri-

chlorophenyl, 2,4,6-trimethyl-phenyl, 2,4-dibromo-3,5-dichloro-phenyl, 2,4-dibromo-6-fluoro-phenyl, 2,4-dichloro-6-methyl-phenyl, 2,6-dibromo-4-isopropyl-phenyl, 2,6-dibromo-4-methyl-phenyl, 2,6-dibromo-4-prop-1-yl-phenyl, 2,6-dichloro-4-cyano-phenyl, 2,6-dichloro-4-trifluoromethoxy-phenyl, 2,6-dichloro-4-trifluoromethyl-phenyl,

5 2,6-dichloro-phenyl, 2,6-dimethyl-4-(1,1-dimethylethyl)-phenyl, 2,6-dimethyl-phenyl, 2-bromo-4-fluoro-6-methyl-phenyl, 2-bromo-6-chloro-4-fluoro-phenyl, 4-bromo-2,6-dimethyl-phenyl, 4-chloro-2,6-dimethyl-phenyl, 4-cyano-2,6-dimethyl-phenyl; or L is -X²-Alk-R⁷ wherein -X²-Alk- is -NH-CH₂- and R⁷ phenyl.

10 Still other particular compounds are those compounds of formula (I) where R³ is hydrogen, A is CH, n is 1, and R⁴ is halo, methyl or cyano and is positioned in the 4 position of the phenyl ring.

15 Preferred compounds are those compounds of the present invention wherein L is 2,6-dichlorobenzyl and the NR³(optionally substituted phenyl or pyridyl) moiety represents *p*-cyano-anilino and is in the 2 position of the pyrimidine ring.

Other preferred compounds are those compounds of the present invention wherein Q is hydrogen, L is -X¹-R⁶ wherein X¹ is -NH- and R⁶ is 2,4,6-trimethyl-phenyl or 4-cyano-2,6-dimethylphenyl, the NR³(optionally substituted phenyl or pyridyl) moiety represents *p*-cyano-anilino and is in the 2 position of the pyrimidine ring.

20 25 Still other preferred compounds are those compounds of the present invention wherein L is -X²-Alk-R⁷ wherein X² is -NH-, Alk is methylene and R⁷ is phenyl, 2,6-dichloro-phenyl, 2,4,6-trimethyl-phenyl or 4-cyano-2,6-dimethylphenyl.

More preferred are those compounds of formula (I'-1) wherein R^{4'} is halo, cyano, aminocarbonyl or cyanoC₁₋₆alkyl; n is zero, A is CH, R³ is hydrogen; R⁵ is hydrogen or methyl; Q is hydrogen or NHR¹; and L contains phenyl, 2,4,6-trichloro-phenyl,

30 35 2,4,6-trimethyl-phenyl, 2,4-dibromo-3,5-dichloro-phenyl, 2,4-dibromo-6-fluoro-phenyl, 2,4-dichloro-6-methyl-phenyl, 2,6-dibromo-4-isopropyl-phenyl, 2,6-dibromo-4-methyl-phenyl, 2,6-dibromo-4-prop-1-yl-phenyl, 2,6-dichloro-4-cyano-phenyl, 2,6-dichloro-4-trifluoromethoxy-phenyl, 2,6-dichloro-4-trifluoromethyl-phenyl, 2,6-dichloro-phenyl, 2,6-dimethyl-4-(1,1-dimethylethyl)-phenyl, 2,6-dimethyl-phenyl, 2-bromo-4-fluoro-6-methyl-phenyl, 2-bromo-6-chloro-4-fluoro-phenyl, 4-bromo-2,6-dimethyl-phenyl, 4-chloro-2,6-dimethyl-phenyl, or 4-cyano-2,6-dimethyl-phenyl.

Most preferred are

4-[[4-amino-6-[(2,6-dichlorophenyl)methyl]-2-pyrimidinyl]amino]benzonitrile;

6-[(2,6-dichlorophenyl)methyl]-*N*2-(4-fluorophenyl)-2,4-pyrimidinediamine;
4-[[4-[(2,4-dichlorophenyl)methyl]-6-[(4-hydroxybutyl)amino]-2-pyrimidinyl]amino]-
benzonitrile;
4-[[4-[(2,6-dichlorophenyl)methyl]-6-[(3-hydroxypropyl)amino]-2-pyrimidinyl]amino]-
5 benzonitrile;
N-[2-[(4-cyanophenyl)amino]-6-[(2,6-dichlorophenyl)methyl]-4-pyrimidinyl]-
acetamide;
N-[2-[(4-cyanophenyl)amino]-6-[(2,6-dichlorophenyl)methyl]-4-pyrimidinyl]-
butanamide;
10 4-[[2-amino-6-(2,6-dichlorophenoxy)-4-pyrimidinyl]amino]benzonitrile;
4-[[4-[(2,6-dichlorophenyl)methyl]-6-[(2-hydroxy-2-phenylethyl)amino]-2-
pyrimidinyl]amino]benzonitrile;
4-[[4-[(2,6-dichlorophenyl)methyl]-6-[[3-(2-oxo-1-pyrrolidinyl)propyl]amino]-2-
pyrimidinyl]amino]benzonitrile;
15 4-[[4-[(2,6-dichlorophenyl)methyl]-6-[[2-(2-hydroxyethoxy)ethyl]amino]-2-
pyrimidinyl]amino]benzonitrile monohydrochloride;
4-[[4-[(2,6-dichlorophenyl)methyl]-6-[(2,3-dihydroxypropyl)amino]-2-pyrimidinyl]-
amino]benzonitrile;
4-[[4-[(2,6-dichlorophenyl)methyl]-6-(hydroxyamino)-2-pyrimidinyl]amino]-
20 benzonitrile;
4-[[4-[(2-cyanoethyl)amino]-6-[(2,6-dichlorophenyl)methyl]-2-pyrimidinyl]amino]-
benzonitrile;
4-[[4-[(2,6-dichlorophenyl)methyl]-6-[[2-(1-pyrrolidinyl)ethyl]amino]-2-pyrimidinyl]-
amino]benzonitrile;
25 4-[[4-amino-6-[(2,6-dichlorophenyl)methyl]-5-methyl-2-pyrimidinyl]amino]-
benzonitrile;
*N*2-(4-bromophenyl)-6-[(2,6-dichlorophenyl)methyl]-5-methyl-2,4-pyrimidinediamine;
4-[[4-[(2,4,6-trimethylphenyl)amino]-2-pyrimidinyl]amino]benzonitrile;
4-[[2-[(2,4,6-trimethylphenyl)amino]-4-pyrimidinyl]amino]benzonitrile;
30 4-[[4-[(2,6-dimethylphenyl)amino]-2-pyrimidinyl]amino]benzonitrile;
4-[[4-(2,4,6-trimethylphenoxy)-2-pyrimidinyl]amino]benzonitrile;
4-[[4-[(2,6-dichlorophenyl)thio]-2-pyrimidinyl]amino]benzonitrile;
4-[[4-[[2,6-dibromo-4-(1-methylethyl)phenyl]amino]-2-pyrimidinyl]amino]-
benzonitrile;
35 4-[[4-[[2,6-dichloro-4-(trifluoromethyl)phenyl]amino]-2-pyrimidinyl]amino]-
benzonitrile;
4-[[4-[(2,4-dichloro-6-methylphenyl)amino]-2-pyrimidinyl]amino]benzonitrile;

4-[[2-[(cyanophenyl)amino]-4-pyrimidinyl]amino]-3,5-dimethylbenzonitrile;
4-[[4-[(2,4-dibromo-6-fluorophenyl)amino]-2-pyrimidinyl]amino]benzonitrile;
4-[[4-amino-6-[(2,6-dichlorophenyl)methyl]-5-methyl-2-pyrimidinyl]amino]-
benzeneacetonitrile;

5 4-[[4-[methyl(2,4,6-trimethylphenyl)amino]-2-pyrimidinyl]amino]benzonitrile;
4-[[4-[(2,4,6-trichlorophenyl)amino]-2-pyrimidinyl]amino]benzonitrile;
4-[[4-[(2,4,6-trimethylphenyl)thio]-2-pyrimidinyl]amino]benzonitrile;
4-[[4-[(2,4,6-trimethylphenyl)amino]-2-pyrimidinyl]amino]benzonitrile;
4-[[4-amino-6-[(2,4,6-trimethylphenyl)amino]-2-pyrimidinyl]amino]benzonitrile;

10 4-[[2-amino-6-[(2,4,6-trimethylphenyl)amino]-4-pyrimidinyl]amino]benzonitrile;
4-[[4-(2-bromo-4-chloro-6-methylphenoxy)-2-pyrimidinyl]amino]benzonitrile;
4-[[4-[(4-chloro-2,6-dimethylphenyl)amino]-2-pyrimidinyl]amino]benzonitrile;
3,5-dichloro-4-[[2-[(4-cyanophenyl)amino]-4-pyrimidinyl]amino]benzonitrile;
4-[[4-[[2,6-dichloro-4-(trifluoromethoxy)phenyl]amino]-2-pyrimidinyl]amino]-
15 benzonitrile;

4-[[4-[(2,4-dibromo-3,6-dichlorophenyl)amino]-2-pyrimidinyl]amino]benzonitrile;
4-[[4-[(2,6-dibromo-4-propylphenyl)amino]-2-pyrimidinyl]amino]benzonitrile;
4-[[4-[(2,4,6-trimethylphenyl)amino]-2-pyrimidinyl]amino]benzamide;
4-[[4-[(4-(1,1-dimethylethyl)-2,6-dimethylphenyl)amino]-2-pyrimidinyl]amino]-
20 benzonitrile;

4-[[2-[(4-cyanophenyl)amino]-4-pyrimidinyl]oxy]-3,5-dimethylbenzonitrile;
4-[[4-[(4-chloro-2,6-dimethylphenyl)amino]-5-methyl-2-pyrimidinyl]amino]-
benzonitrile;

4-[[2-[(4-cyanophenyl)amino]-5-methyl-4-pyrimidinyl]amino]-3,5-dimethyl-
25 benzonitrile;

4-[[4-[[4-(1,1-dimethylethyl)-2,6-dimethylphenyl]amino]-5-methyl-2-pyrimidinyl]-
amino]benzonitrile;

4-[[4-[(4-bromo-2,6-dimethylphenyl)amino]-5-methyl-2-pyrimidinyl]amino]-
benzonitrile;

30 4-[[5-methyl-4-[(2,4,6-trimethylphenyl)thio]-2-pyrimidinyl]amino]benzonitrile;
4-[[4-[(2,6-dibromo-4-propylphenyl)amino]-5-methyl-2-pyrimidinyl]amino]-
benzonitrile;

4-[[4-[(2,4,6-trimethylphenyl)amino]-2-pyrimidinyl]amino]benzamide, *N*3-oxide;
*N*2-(4-chlorophenyl)-*N*4-(2,4,6-trimethylphenyl)-2,4-pyrimidinediamine;

35 4-[[4-[[2,6-dibromo-4-(1-methylethyl)phenyl]amino]-5-methyl-2-pyrimidinyl]amino]-
benzonitrile;

4-[[2-[(4-cyanophenyl)amino]-5-methyl-4-pyrimidinyl]amino]-3,5-dimethyl

benzonitrile;

4-[[4-[(phenylmethyl)amino]-2-pyrimidinyl]amino]benzonitrile;


the *N*-oxides, the pharmaceutically acceptable addition salts and the stereochemically isomeric forms thereof.

5

The compounds of formula (I) can be prepared according to art-known procedures.

In particular, compounds of formula (I') can generally be prepared by reacting an intermediate of formula (II-A) wherein W^1 is a suitable leaving group such as, for example, a halogen, with an amino derivative of formula (III) optionally in a solvent such as, for example, water, 2-propanol, diethylether, 1-methyl-2-pyrrolidinone and the like, and optionally in the presence of an acid such as, for example, 1 N hydrochloric acid in diethylether. It may be convenient to perform the reaction under a reaction-inert atmosphere such as, for example, oxygen free argon or nitrogen.


10



In this and the following preparations, the reaction products may be isolated from the reaction medium and, if necessary, further purified according to methodologies generally known in the art such as, for example, extraction, crystallization, distillation, trituration and chromatography.

20

Analogously to the reaction procedure described above, $H-NR^1R^2$ (VI) can also be reacted with an intermediate of formula (II-B).



Suitable solvents for the above reaction include, for instance, 2-propanol or 1,4-dioxane.


In case Q is NR^1R^2 and R^2 contains a hydroxy moiety, it may be convenient to perform

the above reaction with a protected form of intermediate (VI) whereby the hydroxy moiety bears a suitable protecting group P being, for instance, a benzyl, and subsequently removing the protective group according to art-known methodologies, such as, for example, reacting with BBr_3 in dichloromethane under nitrogen atmosphere.

5

It is also possible to react $\text{H-X}^1\text{-R}^6$ with an intermediate of formula (II-C) in a suitable solvent such as, for example, 1,4-dioxane, thus obtaining compounds of formula (I') wherein L is $-\text{X}^1\text{-R}^6$, said compounds being represented by formula (I'-c).

10




Depending on the nature of X^1 a suitable base or acid may be used to improve the reaction rate. For instance, in case X^1 is $-\text{O}-$, sodium hydride may be used as suitable base; or in case X^1 is NR^3 , HCl may be used as a suitable acid.

15 The compounds of formula (I') may further be prepared by converting compounds of formula (I') into each other according to art-known group transformation reactions.

For instance, compounds of formula (I') whereby Q is NR^1R^2 and R^1 and R^2 are taken together to form mono- or di(C_{1-12} alkyl)amino C_{1-4} alkylidene, said compounds being

20 represented by formula (I'-a), may be prepared by reacting a compound of formula (I') wherein R^1 and R^2 are hydrogen, with an intermediate of formula (IV) or a functional derivative thereof.



Also, compounds of formula (I') wherein Q is NR¹R² and R¹ and R² are hydrogen may further be reacted with an acyl halide or an alkyl chloroformate in a reaction-inert solvent such as, for example dichloromethane, in the presence of a suitable base, such as, for example, pyridine, to form the corresponding amide, respectively, carbamate derivative.

Some of the compounds of formula (I') and some of the intermediates in the present invention may contain an asymmetric carbon atom. Pure stereochemically isomeric forms of said compounds and said intermediates can be obtained by the application of art-known procedures. For example, diastereoisomers can be separated by physical methods such as selective crystallization or chromatographic techniques, e.g. counter current distribution, liquid chromatography and the like methods. Enantiomers can be obtained from racemic mixtures by first converting said racemic mixtures with suitable resolving agents such as, for example, chiral acids, to mixtures of diastereomeric salts or compounds; then physically separating said mixtures of diastereomeric salts or compounds by, for example, selective crystallization or chromatographic techniques, e.g. liquid chromatography and the like methods; and finally converting said separated diastereomeric salts or compounds into the corresponding enantiomers. Pure stereochemically isomeric forms may also be obtained from the pure stereochemically isomeric forms of the appropriate intermediates and starting materials, provided that the intervening reactions occur stereospecifically.


An alternative manner of separating the enantiomeric forms of the compounds of formula (I') and intermediates involves liquid chromatography, in particular liquid chromatography using a chiral stationary phase.

The above specified reaction procedures for the preparation of compounds of formula (I') or subgroups thereof, can also be applied for the preparation of compounds of formula (I).

Some of the intermediates and starting materials are known compounds and may be commercially available or may be prepared according to art-known procedures.


Intermediates of formula (II-A) wherein Q is NR¹R², said intermediates being represented by formula (II-A-1), can be prepared by reacting a pyrimidine derivative of formula (V) wherein W² is a suitable leaving group such as, for example, a halogen, with HNR¹R² (VI) in a reaction inert solvent such as, for example, 1,4-dioxane, 2-propanol or the like. Different regio-specific isomers may be formed and can be

separated from one another using suitable separation techniques such as, for example, chromatography.




Intermediates of formula (II-B) can be prepared analogously to the preparation of

5 compounds of formula (I') starting from intermediates (II-A) and (III).



A particular subgroup of the intermediates of formula (II-B) is represented by formula



Particular intermediates of formula (II'-B) are those wherein W¹ is a halogen, more in


10 particular, a chloro atom.

Intermediates of formula (V) whereby Q is NR¹R² and the L is L'-CH₂ and is attached


15 in the 2 position of the pyrimidine ring and W² is chloro, said intermediates being

represented by formula (V-a), can be prepared by reacting an imidamide of formula


(VII) with a propanedioic acid ester of formula (VIII) in a solvent such as, for example, ethanol, and in the presence of, for instance, sodium, and subsequently reacting the thus formed intermediate of formula (IX) with a suitable reagent such as, for example, phosphoryl chloride.




Intermediates of formula (V) whereby Q is NR^1R^2 and L is $\text{L}'\text{-CH}_2$ and is attached in the 4 or 6 position of the pyrimidine ring and W^2 is chloro, said intermediates being represented by formula (V-b), can be prepared by reacting an intermediate of formula (X) with urea or a functional derivative thereof, in a solvent such as, for example, 5 ethanol, and in the presence of, for instance, sodium, and subsequently reacting the thus formed intermediate of formula (XI) with a suitable reagent such as, for example, phosphoryl chloride.



Intermediates of formula (V) wherein Q is NR^1R^2 and L is $\text{L}'\text{-CH}_2$ and is attached anywhere on the pyrimidine ring, said intermediates being represented by formula (V-c), can be prepared by reacting an intermediate of formula (XII-1), for Q is NR^1R^2 and formula (XII-2) for Q is hydrogen, wherein W^2 is a suitable leaving group such as, for example, a halogen, with an intermediate of formula (XIII) wherein W^3 is a suitable leaving group such as, for example, a halogen, according to the procedure of a Grignard reaction. 10 15



Intermediates of formula (V) whereby Q is NR^1R^2 and L is $-\text{O-R}^6$ or $-\text{NH-R}^6$ and is attached in the 4 or 6 position of the pyrimidine ring, said intermediates being represented by formula (V-d), can be prepared by reacting an intermediate of formula (XIV) with an intermediate of formula (XII) wherein W^2 is a suitable leaving group such as, for example, a halogen, in a reaction-inert solvent such as, for example, tetrahydrofuran or 1,4-dioxane, and in the presence of a suitable base such as, for example, potassium hydroxide or diisopropyl ethaneamine, or sodium hydride. 20



The intermediates of formula (V-a) to (V-d) can analogously be prepared for the compounds of formula (I') wherein Q is hydrogen. To this effect, there is one leaving group W^2 less on the pyrimidine ring of the respective starting material.

5

Compounds of formula (I') and some of the intermediates may have one or more stereogenic centers in their structure, present in a R or a S configuration.

The compounds of formula (I') as prepared in the hereinabove described processes may be synthesized as a mixture of stereoisomeric forms, in particular in the form of racemic mixtures of enantiomers which can be separated from one another following art-known resolution procedures. The racemic compounds of formula (I) may be converted into the corresponding diastereomeric salt forms by reaction with a suitable chiral acid. Said diastereomeric salt forms are subsequently separated, for example, by selective or fractional crystallization and the enantiomers are liberated therefrom by alkali. An alternative manner of separating the enantiomeric forms of the compounds of formula (I) involves liquid chromatography using a chiral stationary phase. Said pure stereochemically isomeric forms may also be derived from the corresponding pure stereochemically isomeric forms of the appropriate starting materials, provided that the reaction occurs stereospecifically. Preferably if a specific stereoisomer is desired, said compound will be synthesized by stereospecific methods of preparation. These methods will advantageously employ enantiomerically pure starting materials.

The compounds of the present invention and the intermediates of formula (II'-B) show antiretroviral properties, in particular against Human Immunodeficiency Virus (HIV), which is the aetiological agent of Acquired Immune Deficiency Syndrome (AIDS) in humans. The HIV virus preferentially infects human T-4 cells and destroys them or changes their normal function, particularly the coordination of the immune system. As a result, an infected patient has an everdecreasing number of T-4 cells, which moreover behave abnormally. Hence, the immunological defense system is unable to combat infections and neoplasms and the HIV infected subject usually dies by opportunistic infections such as pneumonia, or by cancers. Other conditions associated with HIV

infection include thrombocytopaenia, Kaposi's sarcoma and infection of the central nervous system characterized by progressive demyelination, resulting in dementia and symptoms such as, progressive dysarthria, ataxia and disorientation. HIV infection further has also been associated with peripheral neuropathy, progressive generalized lymphadenopathy (PGL) and AIDS-related complex (ARC).

The present compounds also show activity against HIV-1 strains that have acquired resistance to art-known non-nucleoside reverse transcriptase inhibitors. They also have little or no binding affinity to human α -1 acid glycoprotein.

Due to their antiretroviral properties, particularly their anti-HIV properties, especially their anti-HIV-1-activity, the compounds of the present invention are useful in the treatment of individuals infected by HIV and for the prophylaxis of these individuals. In general, the compounds of the present invention may be useful in the treatment of warm-blooded animals infected with viruses whose existence is mediated by, or depends upon, the enzyme reverse transcriptase. Conditions which may be prevented or treated with the compounds of the present invention, especially conditions associated with HIV and other pathogenic retroviruses, include AIDS, AIDS-related complex (ARC), progressive generalized lymphadenopathy (PGL), as well as chronic CNS diseases caused by retroviruses, such as, for example HIV mediated dementia and multiple sclerosis.

The compounds of the present invention or any subgroup thereof may therefore be used as medicines against above-mentioned conditions. Said use as a medicine or method of treatment comprises the systemic administration to HIV-infected subjects of an amount effective to combat the conditions associated with HIV and other pathogenic retroviruses, especially HIV-1.

The compounds of the present invention or any subgroup thereof may be formulated into various pharmaceutical forms for administration purposes. As appropriate compositions there may be cited all compositions usually employed for systemically administering drugs. To prepare the pharmaceutical compositions of this invention, an effective amount of the particular compound, optionally in addition salt form, as the active ingredient is combined in intimate admixture with a pharmaceutically acceptable carrier, which carrier may take a wide variety of forms depending on the form of preparation desired for administration. These pharmaceutical compositions are desirable in unitary dosage form suitable, particularly, for administration orally, rectally, percutaneously, or by parenteral injection. For example, in preparing the

compositions in oral dosage form, any of the usual pharmaceutical media may be employed such as, for example, water, glycols, oils, alcohols and the like in the case of oral liquid preparations such as suspensions, syrups, elixirs and solutions; or solid carriers such as starches, sugars, kaolin, lubricants, binders, disintegrating agents and

5 the like in the case of powders, pills, capsules, and tablets. Because of their ease in administration, tablets and capsules represent the most advantageous oral dosage unit forms, in which case solid pharmaceutical carriers are obviously employed. For parenteral compositions, the carrier will usually comprise sterile water, at least in large part, though other ingredients, for example, to aid solubility, may be included.

10 Injectable solutions, for example, may be prepared in which the carrier comprises saline solution, glucose solution or a mixture of saline and glucose solution. Injectable suspensions may also be prepared in which case appropriate liquid carriers, suspending agents and the like may be employed. Also included are solid form preparations which are intended to be converted, shortly before use, to liquid form preparations. In the

15 compositions suitable for percutaneous administration, the carrier optionally comprises a penetration enhancing agent and/or a suitable wetting agent, optionally combined with suitable additives of any nature in minor proportions, which additives do not introduce a significant deleterious effect on the skin.

20 It is especially advantageous to formulate the aforementioned pharmaceutical compositions in dosage unit form for ease of administration and uniformity of dosage. Dosage unit form as used herein refers to physically discrete units suitable as unitary dosages, each unit containing a predetermined quantity of active ingredient calculated to produce the desired therapeutic effect in association with the required pharmaceutical

25 carrier. Examples of such dosage unit forms are tablets (including scored or coated tablets), capsules, pills, powder packets, wafers, injectable solutions or suspensions and the like, and segregated multiples thereof.

Those of skill in the treatment of HIV-infection could determine the effective daily

30 amount from the test results presented here. In general it is contemplated that an effective daily amount would be from 0.01 mg/kg to 50 mg/kg body weight, more preferably from 0.1 mg/kg to 10 mg/kg body weight. It may be appropriate to administer the required dose as two, three, four or more sub-doses at appropriate intervals throughout the day. Said sub-doses may be formulated as unit dosage forms,

35 for example, containing 1 to 1000 mg, and in particular 5 to 200 mg of active ingredient per unit dosage form.

The exact dosage and frequency of administration depends on the particular compound

of formula (I) used, the particular condition being treated, the severity of the condition being treated, the age, weight and general physical condition of the particular patient as well as other medication the individual may be taking, as is well known to those skilled in the art. Furthermore, it is evident that said effective daily amount may be lowered or 5 increased depending on the response of the treated subject and/or depending on the evaluation of the physician prescribing the compounds of the instant invention. The effective daily amount ranges mentioned hereinabove are therefore only guidelines and are not intended to limit the scope or use of the invention to any extent.

10 Also, the combination of an antiretroviral compound and a compound of the present invention can be used as a medicine. Thus, the present invention also relates to a product containing (a) a compound of the present invention, and (b) another antiretroviral compound, as a combined preparation for simultaneous, separate or sequential use in anti-HIV treatment. The different drugs may be combined in a single 15 preparation together with pharmaceutically acceptable carriers. Said other antiretroviral compounds may be known antiretroviral compounds such as nucleoside reverse transcriptase inhibitors, e.g. zidovudine (3'-azido-3'-deoxythymidine, AZT), didanosine (dideoxy inosine; ddI), zalcitabine (dideoxycytidine, ddC) or lamivudine (3'-thia-2'-3'-dideoxycytidine, 3TC) and the like; non-nucleoside reverse transcriptase 20 inhibitors such as suramine, foscarnet-sodium (trisodium phosphono formate), nevirapine (11-cyclopropyl-5,11-dihydro-4-methyl-6H-dipyrido[3,2-b:2',3'-e] [1,4]diazepin-6-one), sustiva (efavirenz), tacrine (tetrahydroaminoacridine) and the like; compounds of the TIBO (tetrahydro-imidazo[4,5,1-jk][1,4]-benzodiazepine-2(1H)-one and thione)-type e.g. (S)-8-chloro-4,5,6,7-tetrahydro-5-methyl-6-(3-methyl- 25 2-butenyl)imidazo-[4,5,1-jk][1,4]benzodiazepine-2(1H)-thione; compounds of the α -APA (α -anilino phenyl acetamide) type e.g. α -[(2-nitro-phenyl)amino]-2,6-dichloro-benzene-acetamide and the like; TAT-inhibitors, e.g. RO-5-3335 and the like; protease inhibitors e.g. indinavir, ritonavir, saquinavir and the like; NMDA receptor inhibitors e.g. pentamidine; α -glycosidase inhibitor e.g. castanospermine and the like; Rnase H 30 inhibitor e.g. dextran (dextran sulfate) and the like; or immunomodulating agents, e.g. levamisole, thymopentin and the like.

The following examples are intended to illustrate the present invention.

Experimental part

35 A. Intermediate compounds

Example A1

a) A solution of 2,6-dichlorobenzylchloride (0.102 mol) in 1,1-diethylether (10 ml) was added dropwise to magnesium (0.102 mol) in 1,1-diethylether (60 ml). The

reaction was initiated by adding 2 drops of 1,2-dibromoethane. After most of magnesium disappeared, 2,4,6-trichloropyrimidine (0.051 mol) in 1,1-diethylether (30 ml) was added. The mixture was stirred overnight at room temperature. The solvent was evaporated and the residue was purified by flash column chromatography over silica gel (eluent: CH_2Cl_2 /hexane 1/2). The desired fractions were collected and the solvent was evaporated, yielding 3.3 g of (21%) 2,4-dichloro-6-[(2,6-dichlorophenyl)methyl]pyrimidine (interm. 1; m.p.: 106-107 °C).

5 b) Intermediate (1) (0.0081 mol) in 2-propanol (100 ml) was heated until complete dissolution. The solution was then transferred into a pressure tube and NH_3 gas was 10 bubbled into it for 20 minutes. Then the mixture was heated to 80 °C for 16 hours. The solvent was evaporated, yielding a residue of two compounds : 2-chloro-6-[(2,6-dichlorophenyl)methyl]-4-pyrimidinamine (interm. 2) and 4-chloro-6-[(2,6-dichlorophenyl)methyl]-2-pyrimidinamine (interm. 3).

Example A2

15 a) Urea (0.03 mol) was added to a mixture of (\pm)-ethyl 2,6-dichloro-phenyl- α -methyl- β -oxobutanoate (0.02 mol) in NaOC_2H_5 in ethanol, (1M; 0.040 mol; 40 ml). The reaction mixture was stirred and refluxed overnight. The solvent was evaporated, water was added and the mixture was neutralized with 0.3 N HOAc. The precipitate was filtered off and was further triturated with ether and then H_2O , then filtered off and 20 dried, yielding 2.2 g (39%) of 6-[(2,6-dichlorophenyl)methyl]-5-methyl-2,4(1H,3H)-pyrimidinedione (interm. 4).

25 b) A mixture of intermediate (4) (0.0095 mol) in phosphoryl chloride (50 ml) was stirred and refluxed overnight. Excess of phosphoryl chloride was then evaporated. Ice-water was added to the residue. A white precipitate was formed, filtered off and dried. The residue was purified by flash column chromatography over silica gel (eluent: CH_2Cl_2). The desired fractions were collected and the solvent was evaporated, yielding 2.06 g (67%) of 2,4-dichloro-6-[(2,6-dichlorophenyl)methyl]-5-methyl-pyrimidine (interm. 5).

30 c) 4-chloro-6-[(2,6-dichlorophenyl)methyl]-5-methyl-2-pyrimidinamine (interm. 6) and 2-chloro-6-[(2,6-dichlorophenyl)methyl]-5-methyl-4-pyrimidinamine (interm. 7) were prepared from intermediate 5 following the procedures as described in example A1b.

Example A3

35 a) To the stirred solution of 2,6-dichlorobenzeneethanimidamide HCl (1:1), (0.0042 mol) in ethanol (20 ml), a solution of sodium (0.013 mol) in ethanol (10 ml) was added dropwise first and then propanedioic acid, diethyl ester (0.0109 mol) was added. The

reaction mixture was stirred and refluxed for 4 hours and then stirred at room temperature overnight. After adding another equivalent of propanedioic acid, diethyl ester (stirring and refluxing it overnight), the solvent was evaporated and the residue was dissolved in water and acidified with 1 N HCl. The solid was filtered off, washed with water and dried, yielding 0.87 g (76.4%) of 2-[(2,6-dichloro-phenyl)methyl]-4,6-pyrimidinediol (interm. 8).

7 b) 6-chloro-2-[(2,6-dichloro-phenyl)methyl]-4-pyrimidinamine (interm. 9) was prepared starting from intermediate 8 according to the procedures described in example A.1.b, A2.b & A2.c.

10 Example A4

4-Amino-1-butanol (1.57 ml) was added to a solution of intermediate (1) (0.008 mol) in 1,4-dioxane (20 ml) under Argon. The reaction mixture was stirred for 2 hours at room temperature. The solvent was evaporated. The residue was purified by flash column chromatography over silica gel (eluent gradient: $\text{CH}_2\text{Cl}_2/\text{CH}_3\text{OH}$: from 100/0 to 98/2). The pure fractions were collected and the solvent was evaporated, yielding 2.05 g of a mixture of 4-[[2-chloro-6-[(2,6-dichloro-phenyl)methyl]-4-pyrimidinyl]-amino]-1-butanol (interm. 10) and 4-[[4-chloro-6-[(2,6-dichloro-phenyl)methyl]-2-pyrimidinyl]amino]-1-butanol (interm. 11).

Example A5

20 a) Potassium hydroxide/ethanol (10%; 0.035 mol) was added to a solution of 2,6-dichlorophenol (0.035 mol) in tetrahydrofuran (100 ml). The mixture was stirred and 2,4,6-trichloropyrimidine (0.044 mol) was added. The mixture was stirred overnight at 60 °C. The reaction was quenched with NaOH 1N solution. The aqueous layers were extracted with EtOAc several times and then the organic layers were combined and washed with NaOH 3N and saturated NaCl, dried and concentrated. The residue was recrystallized from CH_2Cl_2 /hexane. The precipitate was filtered off and dried, yielding 5.98 g 2,4-dichloro-6-(2,6-dichlorophenoxy)pyrimidine (55%) (interm. 12).

25 b) Reaction under Argon atmosphere. 2,4,6-trimethylaniline (0.0678 mol) was added to 2,4-dichloropyrimidine (0.0664 mol) in 1,4-dioxane (100 ml). *N,N*-di(1-methylethyl)-ethaneamine (0.0830 mol) was added. The reaction mixture was stirred and refluxed for 4 days and the solvent was evaporated. The residue was dissolved in CH_2Cl_2 , washed with a saturated NaHCO_3 solution, then dried (Na_2SO_4), filtered and the solvent was evaporated to give 17.1 g solid residue. This solid was dissolved in CH_2Cl_2 :hexane (1:1; 150 ml), and the resulting solution was concentrated to 100 ml, then filtered. The residue was purified by column chromatography on KP-Sil (eluent: CH_2Cl_2). The desired fractions were collected and the solvent was evaporated. The less polar fraction

was stirred in CH₂Cl₂ for 3 hours and filtered, yielding 0.44 g 4-chloro-*N*-(2,4,6-trimethylphenyl)-2-pyrimidinamine (intermediate 48). A second fraction was recrystallized from acetonitrile, filtered off and dried, yielding 2-chloro-*N*-(2,4,6-trimethyl-phenyl)-4-pyrimidinamine (intermediate 49).

5 Example A6

Pyridine (1 ml) was added to a mixture of 4-[[4-amino-6-[(2,6-dichloro-phenyl)-methyl]-2-pyrimidinyl]amino]benzonitrile (0.00135 mol) in CH₂Cl₂ (19 ml). A solution of chloroethanoyl chloride (0.001375 mol) in CH₂Cl₂ (0.5 ml) was added dropwise on an ice bath. The mixture was stirred at room temperature for 2 hours.

10 More chloroethanoyl chloride (0.00625 mol) in CH₂Cl₂ (0.5 ml) was added. The mixture stood in the refrigerator overnight. The solvent was evaporated. The residue was treated with a saturated Na₂CO₃ solution and the mixture was extracted with CH₂Cl₂. The separated organic layer was dried, filtered and concentrated. The residue was purified by flash column chromatography over silica gel (eluent: CH₂Cl₂/CH₃OH/NH₄OH 99/1/0.1). The desired fractions were collected and the solvent was evaporated, yielding 0.22 g (36.5%) of 2-chloro-*N*-[6-[(2,6-dichloro-phenyl)methyl]-2-[(4-cyano-phenyl)amino]-4-pyrimidinyl]acetamide (interm. 13).

15 Example A7

A mixture of 4-[(4-chloro-2-pyrimidinyl)amino]benzonitrile (0.005 mol) and nitryl tetrafluoroborate (0.0025 mol) in acetonitrile (5 ml) was stirred at room temperature for 4 h. The material was quenched with saturated bicarbonate (50 ml) on cracked ice. The mixture was allowed to reach room temperature, and the yellow solid was filtered off. The solid was adsorbed onto silica and purified by column chromatography (eluent: 30%, 50%, 60%, 70% CH₂Cl₂ in hexanes). The solvent of the desired fraction was evaporated and the residue was dried, yielding 0.89 g (64%) of 3-nitro-4-[(4-chloro-2-pyrimidinyl)amino]benzonitrile.(interm. 51)


20 Example A8

A mixture of 2,6-dichloro-*N*-(2,4,6-trimethylphenyl)-4-pyrimidinamine (0.00376 mol) in a 2.0 M solution of NH₃ in 2-propanol (25 ml) and a 0.5 M solution of NH₃ in dioxane (25 ml) was heated in a pressure sample at 110-115 °C for 24 hours. The solvent was evaporated, and the residue was chromatographed on Biotage (eluent: 1:1 CH₂Cl₂:hexane). The desired fractions were collected and the solvent was evaporated, yielding a mixture of 0.523 g of 2-chloro-*N*4-(2,4,6-trimethylphenyl)-4,6-pyrimidine-diamine (interm. 53) and 0.101 g of 6-chloro-*N*4-(2,4,6-trimethylphenyl)-2,4-pyrimidinediamine. (interm. 50)

Tables 1 and 2 list intermediates which were prepared analogous to one of the above


examples.

Table 1a




Int. No.	Ex. No.	R ^a	R ^b	R ^c	X	R ⁵	R	physical data melting point
6	A2c	Cl	H	Cl	CH ₂	CH ₃	-NH ₂	-
15	A1b	Cl	H	Cl	CH ₂	H	-NH-CH ₃	-
16	A1b	Cl	H	Cl	O	H	-NH-CH ₃	152-155°C
17	A1b	Cl	H	Cl	O	H	-NH ₂	-
19	A4	Cl	H	Cl	CH ₂	H	-NH-(CH ₂) ₃ -OH	-
20	A4	Cl	H	Cl	CH ₂	H	-NH-(CH ₂) ₂ -OH	111-113°C
21	A4	Cl	H	Cl	CH ₂	H	-NH-CH ₂ -CH(OH)-C ₆ H ₅	133-134°C
22	A4	Cl	H	Cl	CH ₂	H		-
23	A4	Cl	H	Cl	CH ₂	H	-NH-(CH ₂) ₂ -O-(CH ₂) ₂ OH	99-107°C
24	A4	Cl	H	Cl	CH ₂	H	-NH-(CH ₂) ₂ -(4-OCH ₃ -C ₆ H ₄)	138-140°C
25	A4	Cl	H	Cl	CH ₂	H	-NH-(CH ₂) ₂ -(3-OCH ₃ -C ₆ H ₄)	132-135°C
26	A4	Cl	H	Cl	CH ₂	H	-NH-CH ₂ -CH(OH)-CH ₂ OH	116-118°C
27	A4	Cl	H	Cl	CH ₂	H	-NH-CH ₂ -C ₆ H ₅	137-139°C
28	A4	Cl	H	Cl	CH ₂	H	-NH-(CH ₂) ₂ -(2-thienyl)	113-114°C
29	A4	Cl	H	Cl	CH ₂	H	-NH-(CH ₂) ₂ -(2-pyridyl)	113.5-114°C
31	A4	Cl	H	Cl	CH ₂	H	-NH-(CH ₂) ₂ CN	151-153°C
48	A5b	CH ₃	CH ₃	CH ₃	NH	H	-H	142-143°C
50	A8	CH ₃	CH ₃	CH ₃	NH	H	-NH ₂	


Table 1b



Int. No.	Ex. No.	R ^a	R ^b	R ^c	X	R ⁵	R	physical data melting point
14	A2b	H	CN	H	NH	H	H	
18	A5b	CH ₃	CH ₃	CH ₃	NH	CH ₃	H	
30	A2b	H	CN	H	NH	CH ₃	H	
51	A7	NO ₂	CN	H	NH	H	H	142-144°C

Table 2



Int. No.	Ex. No.	R ^a	R ^b	R ^c	X	R ⁵	R	physical data
7	A2c	Cl	H	Cl	CH ₂	CH ₃	-NH ₂	
32	A1b	Cl	H	Cl	CH ₂	H	-NH-CH ₃	-
33	A4	Cl	H	Cl	CH ₂	H	-NH-(CH ₂) ₂ -(1-pyrrolidinyl)	134-135°C
34	A4	Cl	H	Cl	CH ₂	H	-NH-(CH ₂) ₂ -(2-pyridyl)	130-133°C
35	A4	Cl	H	Cl	CH ₂	H	-NH-(CH ₂) ₂ -(2-thienyl)	98-99°C
36	A4	Cl	H	Cl	CH ₂	H	-NH-(CH ₂) ₂ -(3-OCH ₃ -C ₆ H ₄)	104-109°C
37	A4	Cl	H	Cl	CH ₂	H	-NH-(CH ₂) ₂ -(4-OCH ₃ -C ₆ H ₄)	149-150°C
38	A4	Cl	H	Cl	CH ₂	H	-NH-(CH ₂) ₂ CN	137-139°C
39	A4	Cl	H	Cl	CH ₂	H	-NH-(CH ₂) ₂ -O-(CH ₂) ₂ OH	-
40	A4	Cl	H	Cl	CH ₂	H	-NH-(CH ₂) ₂ OH	170-173°C
41	A4	Cl	H	Cl	CH ₂	H	-NH-(CH ₂) ₃ -O-CH(CH ₃) ₂	-
42	A4	Cl	H	Cl	CH ₂	H	-NH-(CH ₂) ₃ -OH	-
43	A4	Cl	H	Cl	CH ₂	H	-NH-CH ₂ -C ₆ H ₅	171-172°C
45	A4	Cl	H	Cl	CH ₂	H	-NH-CH ₂ -CH(OH)-CH ₂ OH	>60°C
46	A4	Cl	H	Cl	CH ₂	H	-NH-O-CH ₂ -C ₆ H ₅	137-141°C
47	A4	Cl	H	Cl	CH ₂	H	—NH-(CH ₂) ₃ —N— 	55-60°C
49	A5b	CH ₃	CH ₃	CH ₃	NH	H	H	
52	A4	Cl	H	Cl	CH ₂	H	-NH-CH ₂ -CH(OH)-C ₆ H ₅	75-83°C
53	A1b	CH ₃	CH ₃	CH ₃	NH	H	-NH ₂	
54	A5b	CH ₃	CH ₃	CH ₃	NH	CH ₃	H	
55	A5a	Cl	Cl	Cl	-O-	H	H	159-161°C

B. Compounds of formula (I')**Example B1**

A mixture of intermediate (42) and intermediate (19) (0.004 mol) and 4-amino-benzonitrile (0.0084 mol) were combined in a sealed tube and heated for 16 hours at 5 160°C under Argon. The reaction mixture was allowed to cool to room temperature and dissolved in CH₂Cl₂/CH₃OH 90/10 (20 ml) and 5 g of silica gel was added. After evaporating the solvent, the residue was purified by flash column chromatography over 10 silica gel (eluent gradient: CH₂Cl₂/CH₃OH: from 100/0 to 97/3). The desired fraction was collected and the solvent was evaporated, yielding 0.31 g (18.1%) of 4-[[4-[(2,6-di-chloro-phenyl)methyl]-6-[(3-hydroxypropyl)amino]-2-pyrimidinyl]amino]benzonitrile (compound 3).

Example B2

Intermediates (47) and (22) (0.00399 mol) and 4-aminobenzonitrile (0.0012 mol) in 1-methyl-2-pyrrolidinone (3 ml) was stirred for 16 hours at 130 °C under Argon. Then, 15 the reaction mixture was cooled to room temperature and quenched with H₂O (200 ml). A precipitate formed, which was stirred for 16 hours, and separated by filtration over Celite. The residue was dissolved in CH₃OH/CH₂Cl₂ (10%, 200 ml), dried over K₂CO₃, filtered, and evaporated. This resulting material was further purified by flash column chromatography over silica gel (gradient eluent: CH₂Cl₂/CH₃OH from 100/0 to 95/5). 20 The desired fraction was collected and the solvent was evaporated, yielding 0.43 g (21.7%) of 4-[[6-[(2,6-dichloro-phenyl)methyl]-2-[[3-(2-oxo-1-pyrrolidinyl)propyl]-amino]-4-pyrimidinyl]amino]benzonitrile (comp. 39; 104-114°C).

Example B3

HCl/diethyl ether (1N; 2.77 ml) was stirred into a solution of intermediate (33) 25 (0.00277 mol) in 1-methyl-2-pyrrolidinone (4 ml) under N₂ atmosphere. The reaction mixture was heated for 5 minutes. Next, 4-aminobenzonitrile (0.0061 mol) was added and the reaction was heated at 100 °C for 16 hours. Then, the reaction mixture was cooled to room temperature and diluted with ethylacetate (10 ml). The organic layer was washed with NaOH (1 N; 2 x 100 ml), H₂O (2 x 100 ml), brine (50 ml), 30 respectively, dried, filtered and the filtrate was evaporated. The crude material was purified by flash chromatography (eluent: 2.5-7.5% of CH₃OH containing 10% NH₄OH in CH₂Cl₂). The desired fractions were collected and the solvent was evaporated. The residue was dried, yielding 0.160 g (12.0%) of 4-[[4-[(2,6-dichloro-phenyl)methyl]-6-[[2-(1-pyrrolidinyl)ethyl]amino]-2-pyrimidinyl]amino]benzonitrile (comp. 13; 35 mp. 80-85°C).

Example B4

A slurry of intermediate (14) (0.005 mol) in CH_2Cl_2 (150 ml) was stirred rapidly and cooled to 0 °C under nitrogen. BBr_3 (0.015 mol) was introduced by syringe. The reaction mixture was stirred rapidly for two hours. The reaction mixture was recooled 5 to 0 °C and quenched with NaOH (aq. 1 N, 25 ml). The biphasic partial quench mixture gives a precipitate which was filtered off and dried, yielding 2.5 g (91%) of 4-[[4-[(2,6-dichlorophenyl)methyl]-6-(hydroxyamino)-2-pyrimidinyl]amino]-benzonitrile dihydrobromide.pentahydrate (comp. 15; mp. 240-244°C).

Example B5

10 1,1-Dimethoxy-*N,N*-dimethylmethanamine (0.152 mol) was added to 4-[[4-amino-6-[(2,6-dichlorophenyl)methyl]-2-pyrimidinyl]amino]benzonitrile (0.0008 mol). The mixture was stirred at room temperature for 2 days and then concentrated. The crude product was purified by flash chromatography over silica gel (eluent: $\text{CH}_2\text{Cl}_2/\text{CH}_3\text{OH}$ 99/1). The desired fraction was collected and the solvent was evaporated. The 15 resulting residue was triturated with hexane, yielding 0.15 g (42%) of *N*-[2-[(4-cyano-phenyl)amino]-6-[(2,6-dichlorophenyl)methyl]-4-pyrimidinyl]-*N,N*-dimethyl-methanimidamide (comp. 26; mp. 175-180°C).

Example B6

20 Piperidine (0.12 ml) was added to a mixture of intermediate (13) (0.00047 mol) in terahydrofuran (20 ml). The mixture was stirred at room temperature for 4 hours. More piperidine (0.14 ml) was added. The mixture was stirred for another 2 hours. The solvent was evaporated. The residue was purified by flash column chromatography over silica gel ($\text{CH}_2\text{Cl}_2/\text{CH}_3\text{OH}/\text{NH}_4\text{OH}$ 99/1/0.1). The desired fractions were collected and the solvent was evaporated, yielding 0.05 g (21.5%) of *N*-[6-[(2,6-dichlorophenyl)methyl]-2-[(4-cyano-phenyl)amino]-4-pyrimidinyl]-1-piperidine-acetamide (comp. 25; mp. 175-180°C).

Example B7

30 Pyridine (0.014 mol) was added to a mixture of 4-[[4-amino-6-[(2,6-dichlorophenyl)-methyl]-2-pyrimidinyl]amino]benzonitrile (0.0013 mol) in CH_2Cl_2 . A solution of octanoyl chloride (1.5 equiv) in CH_2Cl_2 (0.5 ml) was added dropwise. The mixture was stirred at room temperature for 2 hours. More octanoyl chloride (3.5 equiv) in CH_2Cl_2 was added dropwise. The mixture was stirred. The solvent was then evaporated. The residue was treated with a saturated aqueous NaHCO_3 solution and the mixture was extracted with CH_2Cl_2 . The separated organic layer was dried, filtered and the solvent 35 was evaporated to give the crude product. The residue was recrystallized from CHCl_3 and hexane, yielding 0.443 g (68.6%) of *N*-[6-[(2,6-dichlorophenyl)methyl]-2-[(4-

cyano-phenyl)amino]-4-pyrimidinyl]octanamide (comp. 17; mp. 135-137°C).

Example B8

a) A mixture of intermediate 49 (0.082 mol) and 5.4 N HCl in 2-propanol (0.086 mol) in water (300 ml) was stirred and warmed to 40-45 °C over 30 minutes. 4-Amino-
5 benzonitrile (0.242 mol) was added at 40-45 °C. The reaction mixture was stirred and
refluxed for 4.5 hours, then cooled to room temperature. The mixture was alkalized by
portionwise addition of NaHCO₃. This mixture was extracted with ethylacetate. The
organic layer was separated, washed with brine, dried, filtered and the solvent was
evaporated. This fraction was stirred in ethanol p.a. (100 ml), filtered off, washed with
10 ethanol (50 ml), then dried, yielding 23.1 g (86%) 4-[[4-[(2,4,6-trimethylphenyl)-
amino]-2-pyrimidinyl]amino]benzonitrile (compound 52).

b) A mixture of 4-[(4-chloro-2-pyrimidinyl)amino]benzonitrile (0.021 mol) and HCl in
2-propanol (0.0095 mol) in water (30 ml) was stirred for one hour at 45 °C. 4-amino-
15 3,5-dimethyl-benzonitrile (0.025 mol) was added and the reaction mixture was stirred
and refluxed overnight. The mixture was cooled to room temperature, then neutralized
with NaHCO₃. This mixture was extracted with ethylacetate. The separated organic
layer was washed with brine, dried, filtered and the solvent evaporated. The residue was
crystallized from CH₃CN, filtered off and dried. The residue was stirred in boiling
CH₂Cl₂ (20 ml), then filtered off and dried. The residue was crystallized from methyl
20 isobutyl keton, filtered off and dried, yielding 0.3 g of 4-[[2-[(cyanophenyl)amino]-4-
pyrimidinyl]amino]-3,5-dimethylbenzonitrile (compound 69).

Example B9

a) 4-[(4-chloro-2-pyrimidinyl)amino]benzonitrile (0.003 mol), 2,6-dibromo-4-methyl-
benzenamine (0.006 mol) and 1 M HCl in diethyl ether (4.5 ml) in 1,4-dioxane (10 ml)
25 were combined in a tube and heated under Ar until all diethyl ether had evaporated. The
tube was sealed and heated at 170 °C for 2.5 days. Silica gel was added, and the solvent
was evaporated. The residue was purified by flash column chromatography over silica
gel (eluent gradient: CH₂Cl₂:CH₃OH:NH₄OH 100:0:0 to 99:0.9:0.1). The desired
fractions were collected and the solvent was evaporated. The residue was recrystallized
30 from acetonitrile, filtered off and dried, yielding 0.22 g (15.9%) of 4-[[4-[(2,6-dibromo-
4-methylphenyl)amino]-2-pyrimidinyl]amino]benzonitrile (compound 61).

b) 4-[[4-[(4-chloro-5-methyl-2-pyrimidinyl)amino]benzonitrile (0.01541 mol),
4-amino-3,5-dimethyl-benzonitrile (0.00219 mol), 1-methyl-2-pyrrolidinone (4 ml),
1,4-dioxane (15 ml) and diisopropylethylamine (0.0154 mol) were combined in a flask
35 under a stream of argon and heated at 160-230 °C for 16 hours. CH₂Cl₂ and 1N NaOH
were added, and the mixture was stirred 1 hour and filtered to give a brown solid (*).
The CH₂Cl₂ filtrate was separated and was evaporated and purified by flash column

chromatography (eluent: 2% CH₃OH/CH₂Cl₂). The desired fractions were combined, evaporated and the residue was stirred in CH₂Cl₂. The solid precipitate was filtered off, combined with the brown solid (*) and recrystallized from CH₃CN. The precipitate was filtered off and dried, yielding 1.57 g (29%) of 4-[[2-[(4-cyanophenyl)amino]-5-methyl-4-pyrimidinyl]amino]-3,5-dimethylbenzonitrile (compound 89).

5 c) 2-[(4-cyanophenyl)amino]-4-pyrimidinyl trifluoromethanesulfonate (0.0022 mol) and 2,6-dichloro-4-(trifluoromethyl)-benzenamine (0.0044 mol) were combined in 1,4-dioxane (2.5 ml) and heated in a sealed tube under Ar at 170 °C for 40 hours. The reaction mixture was allowed to cool to room temperature. Silica gel was added, and 10 the solvent was evaporated. The residue was purified by flash column chromatography over silica gel (eluent gradient: CH₂Cl₂:CH₃OH:NH₄OH 100:0:0 to 97:2.7:0.3). The desired fractions were collected and the solvent was evaporated. The residue was recrystallized from CH₃CN, filtered off and dried, yielding 0.086 g (9.2%) of 4-[[4-[[2,6-dichloro-4-(trifluoromethyl)-phenyl]amino]-2-pyrimidinyl]amino]benzonitrile 15 (compound 66).

Example B10

To a suspension of NaH (0.006 mol) in 1,4-dioxane (30 ml), 2,4,6-trimethyl-phenol (0.006 mol) was added. The mixture was stirred for 15 minutes at room temperature, and a clear solution formed. 4-[(4-chloro-2-pyrimidinyl)amino]benzonitrile (0.004 mol) was added, and the reaction mixture was heated to reflux under Argon for 15 hours. The reaction mixture was allowed to cool to room temperature, 0.5 ml of water was added, followed by 4 g of silica gel, and the solvent was evaporated. The residue was purified by flash column chromatography over silica gel (eluent gradient: CH₂Cl₂:CH₃OH 100:0:0 to 97:3). The pure fractions were collected and the solvent 20 was evaporated, yielding 1.18 g (89.4%) of 4-[[4-(2,4,6-trimethylphenoxy)-2-pyrimidinyl]amino]benzonitrile (compound 58).

Example B11

Compound (52) (0.0015 mol) was stirred in boiling ethanol (8 ml). 6 M HCl in 2-propanol (0.0015 mol) was added and the salt was allowed to crystallize out 30 overnight at room temperature. The precipitate was filtered off, washed with 2-propanol and dried, yielding 0.47 g (86%) of 4-[[4-[(2,4,6-trimethyl-phenyl)amino]-2-pyrimidinyl]amino]benzonitrile hydrochloride (1:1) (compound 53).


Example B12

A mixture of compound (52) (0.00303 mol) and NaBO₃.4H₂O (0.00911 mol) in CH₃OH 35 (30 ml) and H₂O (10 ml) was stirred and refluxed for 4 days. The reaction mixture was

cooled. The precipitate was filtered off and the precipitate (*) was purified by flash column chromatography over silica gel (eluent: $\text{CH}_2\text{Cl}_2/\text{CH}_3\text{OH}$ gradient from 100/0 to 95/5). The desired fractions were collected and the solvent was evaporated, yielding 0.586 g (56%) of 4-[[4-[(2,4,6-trimethylphenyl)amino]-2-

5 pyrimidinyl]amino]benzamide (compound 100). The filtrate (*) was purified by reversed-phase HPLC (eluent gradient: ((0.5% ammoniumacetate in H_2O)/ CH_3CN 90/10)/ $\text{CH}_3\text{OH}/\text{CH}_3\text{CN}$ (0 minutes) 75/25/0, (44 minutes) 0/50/50, (57 minutes) 0/0/100, (61.1-70 minutes) 75/25/0). Three desired fraction groups were collected and their solvent was evaporated, yielding 0.18 g of 4-[[4-[(2,4,6-trimethylphenyl)amino]-2-pyrimidinyl]amino]benzamide, *N*3-oxide (compound 106) and 0.030 g of 10 4-[[4-[(2,4,6-trimethylphenyl)amino]-2-pyrimidinyl]amino]benzamide, *N*1-oxide (compound 107).


Tables 3, 4, 5 and 6 list the compounds of formula (I) that were prepared according to one of the above examples.

15 Table 3

Co. No.	Ex. No.	NR ¹ R ²	physical data (melting point in °C)
1	B2	-NH-(CH ₂) ₄ -OH	161-163°C
2	B2	-NH-(CH ₂) ₂ -OH	207-210°C
3	B2	-NH-(CH ₂) ₃ -OH	152-154°C
4	B2	-NH-CH ₂ -CHOH-C ₆ H ₅	158-165°C
5	B2	—NH-(CH ₂) ₃ -N() ²	48-56°C
6	B2	-NH-(CH ₂) ₂ -O-(CH ₂) ₂ -OH	162-175°C; HCl (1:1)
7	B2	-NH-(CH ₂) ₃ -O-CH(CH ₃) ₂	181-182°C; HCl (1:1)
8	B2	-NH-(CH ₂) ₂ -(3-OCH ₃ -C ₆ H ₄)	72-80°C
9	B2	-NH-CH ₂ -CHOH-CH ₂ OH	189-192°C
10	B2	-NH-(CH ₂) ₂ -(4-OCH ₃ -C ₆ H ₄)	72-80°C

Co. No.	Ex. No.	NR ¹ R ²	physical data (melting point in °C)
11	B2	-NH-O-CH ₂ -C ₆ H ₅	-
12	B2	-NH-CH ₂ -C ₆ H ₅	-
13	B3	-NH-(CH ₂) ₂ -(1-pyrrolidinyl)	80-85°C
14	B2	-NH-(CH ₂) ₂ -(2-thienyl)	-
15	B4	-NH-OH	240-244°C
16	B2	-NH-(CH ₂) ₂ -(2-pyridyl)	75-80°C
17	B7	-NH-CO-C ₇ H ₁₅	135-137°C
18	B7	-NH-CO-C ₁₁ H ₂₃	130-135°C
19	B2	-NH-(CH ₂) ₂ -CN	255°C; HCl (1:1)
20	B7	-NH-CO-O-C ₂ H ₅	>200°C
21	B7	-NH-CO-CH ₃	128-130°C
22	B7	-NH-CO-C ₃ H ₇	>200°C
23	B1	-NH ₂	94-97°C
24	B1	-NH-CH ₃	178-180°C
25	B6	-NH-CO-CH ₂ -(1-piperidinyl)	175-180°C
26	B5	-N=CH-N(CH ₃) ₂	175-180°C

Table 4



Co. No.	Ex. No.	R'	R''	R ⁵	physical data (melting point)
27	B1	4-Br-C ₆ H ₄	H	H	-
28	B1	H	4-Br-C ₆ H ₄	H	-
29	B1	4-Cl-C ₆ H ₄	H	H	-
30	B1	H	4-Cl-C ₆ H ₄	H	-
31	B1	H	(3-Br-6-pyridyl)	H	-
32	B1	(3-Br-6-pyridyl)	H	H	-
33	B1	4-F-C ₆ H ₄	H	H	77-80°C
34	B1	H	4-F-C ₆ H ₄	H	>200°C
35	B1	4-CH ₃ -C ₆ H ₄	H	H	76-79°C
36	B1	H	4-CH ₃ -C ₆ H ₄	H	183-186°C




Co. No.	Ex. No.	R'	R''	R ⁵	physical data (melting point)
37	B1	C ₆ H ₅	H	H	85-90°C
38	B1	H	C ₆ H ₅	H	182-187°C
39	B2		4-CN-C ₆ H ₄	H	104-114°C
40	B2	(CH ₂) ₂ -OH	4-CN-C ₆ H ₄	H	247-250°C; HCl (1:1)
41	B1	CH ₃	4-CN-C ₆ H ₄	H	>200°C
42	B1	(CH ₂) ₃ -OH	4-CN-C ₆ H ₄	H	91-105°C
43	B2	(CH ₂) ₄ -OH	4-CN-C ₆ H ₄	H	161-163°C
45	B1	H	4-CN-C ₆ H ₄	H	>200°C
46	B1	H	4-CN-C ₆ H ₄	CH ₃	>200°C
47	B1	4-CN-C ₆ H ₄	H	CH ₃	>200°C
48	B1	H	4-Br-C ₆ H ₄	CH ₃	>200°C
49	B1	4-Br-C ₆ H ₄	H	CH ₃	168-170°C


Table 5



Co. No.	Ex. No.	R'	R''	R'''	R ⁵	physical data
50	B1	NH ₂	4-CN-C ₆ H ₄	O-(2,6-diCl-C ₆ H ₃)	H	>200°C
51	B1	CH ₂ -(2,6-diCl-C ₆ H ₃)	H	-NH-(4-CN-C ₆ H ₄)	H	>200
90	B9a	NH-(2-NO ₂ -4-CN-C ₆ H ₃)	2,4,6-triCH ₃ -C ₆ H ₂	H	H	165-168°C
91		NH-(3-OH-4-CN-C ₆ H ₃)	2,4,6-triCH ₃ -C ₆ H ₂	H	H	
92	B12	NH-(2,6-diCl-C ₆ H ₃)	2,6-diCl-C ₆ H ₃	H	H	164-166°C
93	B9a	NH-(2,4,6-triCH ₃ -C ₆ H ₂)	4-CN-C ₆ H ₄	H	H	267-268°C
94	B1	NH-(4-CN-C ₆ H ₄)	2,4,6-triCH ₃ -C ₆ H ₂	NH ₂	H	263-264°C
95	B1	NH ₂	2,4,6-triCH ₃ -C ₆ H ₂	-NH-(4-CN-C ₆ H ₄)	H	233-234°C
96	B8a	NH-(4-Cl-C ₆ H ₄)	2,4,6-triCH ₃ -C ₆ H ₂	H	H	
97	B8a	NH-(2,4-diF-C ₆ H ₃)	2,4,6-triCH ₃ -C ₆ H ₂	H	H	
98	B8a		2,4,6-triCH ₃ -C ₆ H ₂	H	H	
99	B9a	NH-(2,4,6-triCH ₃ -C ₆ H ₂)	4-CN-C ₆ H ₄	H	CH ₃	200-201°C

Co. No.	Ex. No.	R'	R''	R'''	R ⁵	physical data
100	B11		2,4,6-triCH ₃ -C ₆ H ₂	H	H	
101	B8a		2,4,6-triCH ₃ -C ₆ H ₂	H	H	
102	B8a		2,4,6-triCH ₃ -C ₆ H ₂	H	H	
103	B1		H	-CH ₂ -(2,6-diCl-C ₆ H ₃)	CH ₃	>200°C
104		NH-(4-CN-C ₆ H ₄)	C ₆ H ₅ -CH ₂ -	H	H	
105		NH-(2,4,6-triCH ₃ -C ₆ H ₂)	2,4,6-triCH ₃ -C ₆ H ₂	H	H	

Table 6



Co. No.	Ex. No.	X	R ⁵	R ^{6a}	R ^{6b}	R ^{6c}	R ^{6d}	physical data (salt form; melting point)
52	B8a	NH	H	CH ₃	H	CH ₃	CH ₃	217-218°C
53	B11	NH	H	CH ₃	H	CH ₃	CH ₃	HCl (1:1)
54	B11	NH	H	CH ₃	H	CH ₃	CH ₃	HBr (1:1)
55	B11	NH	H	CH ₃	H	CH ₃	CH ₃	L-tartrate
56	B9a	NH	H	CH ₃	H	Br	CH ₃	HCl (1:1); 214-217°C
57	B9a	NH	H	CH ₃	H	H	CH ₃	HCl (1:1); > 270°C
58	B10	O	H	CH ₃	H	CH ₃	CH ₃	220-222°C
59	B10	S	H	Cl	H	H	Cl	225-226°C
60	B3	O	H	Cl	H	Cl	Cl	279-280°C
61	B9a	NH	H	Br	H	CH ₃	Br	230-233°C
62	B9a	NH	H	Br	H	CH(CH ₃) ₂	Br	198-200°C

Co. No.	Ex. No.	X	R ⁵	R ^{6a}	R ^{6b}	R ^{6c}	R ^{6d}	physical data (salt form; melting point)
63	B3	NH	CH ₃	CH ₃	H	CH ₃	CH ₃	236-237°C
64	B10	O	H	Cl	H	Cl	CH ₃	266-267°C
65	B9a	NH	H	Cl	H	H	Cl	253-255°C
66	B9c	NH	H	Cl	H	CF ₃	Cl	239-240°C
67	B9c	NH	H	Br	H	F	Cl	244-245°C
68	B9a	NH	H	Cl	H	Cl	CH ₃	217°C
69	B8b or B9a	NH	H	CH ₃	H	CN	CH ₃	225-230°C
70	B9c	NH	H	Br	H	Br	F	210-214°C
71	B9c	N(CH ₃)	H	CH ₃	H	CH ₃	CH ₃	218-219°C
72	B9c	NH	H	Cl	H	Cl	Cl	trifluoroacetate (1:1); 225-230°C
73	B10	S	H	CH ₃	H	CH ₃	CH ₃	204.5-208°C
74	B10	O	H	Br	H	Cl	CH ₃	246-249°C
75	B9c	NH	H	CH ₃	H	Cl	CH ₃	206-207°C
76	B9a	NH	H	Cl	H	CN	Cl	>180°C
77	B9c	NH	H	Cl	H	OCF ₃	Cl	185-190°C
78	B9c	NH	H	Br	Cl	Br	Cl	>265°C
79	B9c	NH	H	Br	H	C ₃ H ₇	Br	215-218°C
80	B9a	NH	H	CH ₃	H	C(CH ₃) ₃	CH ₃	203-205°C
81	B10	O	H	CH ₃	H	CN	CH ₃	279-280°C
82	B9c	NH	CH ₃	CH ₃	H	Cl	CH ₃	235-237°C
83	B9b	NH	CH ₃	CH ₃	H	CN	CH ₃	H ₂ O (1:1) trifluoroacetate (1:1); 274-275°C
84	B9c	NH	CH ₃	CH ₃	H	C(CH ₃) ₃	CH ₃	231-232°C
85	B9c	NH	CH ₃	CH ₃	H	Br	CH ₃	218-219°C
86	B9c	S	CH ₃	CH ₃	H	CH ₃	CH ₃	229-230°C
87	B9a	NH	CH ₃	Br	H	C ₃ H ₇	Br	197-198°C
88	B9a	NH	CH ₃	Br	H	CH(CH ₃) ₂	Br	157-158°C
89	B9b	NH	CH ₃	CH ₃	H	CN	CH ₃	>300°C

C. Pharmacological example

Example C.1

A rapid, sensitive and automated assay procedure was used for the *in vitro* evaluation of anti-HIV agents. An HIV-1 transformed T4-cell line, MT-4, which was previously

5 shown (Koyanagi et al., *Int. J. Cancer*, 36, 445-451, 1985) to be highly susceptible to

and permissive for HIV infection, served as the target cell line. Inhibition of the HIV-induced cytopathic effect was used as the end point. The viability of both HIV- and mock-infected cells was assessed spectrophotometrically via the *in situ* reduction of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT). The 50% cytotoxic concentration (CC₅₀ in μ M) was defined as the concentration of compound that reduced the absorbance of the mock-infected control sample by 50%. The percent protection achieved by the compound in HIV-infected cells was calculated by the following formula :

$$\frac{(OD_T)_{HIV} - (OD_C)_{HIV}}{(OD_C)_{MOCK} - (OD_C)_{HIV}} \quad \text{expressed in \%},$$

whereby (OD_T)_{HIV} is the optical density measured with a given concentration of the test compound in HIV-infected cells; (OD_C)_{HIV} is the optical density measured for the control untreated HIV-infected cells; (OD_C)_{MOCK} is the optical density measured for the control untreated mock-infected cells; all optical density values were determined at 540 nm. The dose achieving 50% protection according to the above formula was defined as the 50% inhibitory concentration (IC₅₀ in μ M). The ratio of CC₅₀ to IC₅₀ was defined as the selectivity index (SI). The compounds of formula (I) were shown to inhibit HIV-1 effectively. Particular IC₅₀, CC₅₀ and SI values are listed in Table 7 hereinbelow.

Table 7

Co. No.	IC ₅₀ (μ M)	CC ₅₀ (μ M)	SI	Co. No.	IC ₅₀ (μ M)	CC ₅₀ (μ M)	SI
1	0.027	49.7	1860	56	0.0023	1.9	839
2	0.035	>100	>2890	57	0.0007	0.8	1153
3	0.016	37.4	2558	58	0.0029	> 100	> 34482
4	0.315	>100	>317	59	0.0012	> 100	> 83333
5	0.094	56.2	598	60	0.29	> 100	> 350
6	0.020	24.4	1192	61	0.0007	0.1	155
7	0.975	>100	>102	62	0.0032	8.7	2716
8	8.147	>100	>12	63	0.0017	0.3	198
9	0.037	58.6	1587	64	0.12	> 100	> 840
10	2.529	>100	>39	65	0.18	0.2	1
12	1.683	55.1	32	66	0.0085	19.9	2347
13	0.005	7.8	1557	67	0.0024	0.4	152
14	2.183	89.0	40	68	0.001	1.4	1367
15	0.003	9.0	2857	69	0.0004	4.7	11632
16	0.389	41.2	105	70	0.0006	5.8	9641
17	0.167	9.1	54	71	0.0063	45.8	7275

Co. No.	IC50 (μ M)	CC50 (μ M)	SI	Co. No.	IC50 (μ M)	CC50 (μ M)	SI
18	2.1	59.9	29	72	0.0007	0.5	705
19	0.006	53.6	8642	73	0.0036	> 100	> 27777
20	0.026	36.5	1413	74	0.010	> 100	> 9523
21	0.017	50.6	2910	75	0.0021	1.9	911
22	0.035	12.2	346	76	0.0033	5.2	1580
23	0.001	47.9	59935	77	0.0030	9.6	3188
24	0.020	54.0	2667	78	0.0028	0.4	144
25	0.079	>100	>1272	79	0.0031	4.8	1547
26	0.011	33.5	2990	80	0.011	8.7	771
27	0.017	>20	>1169	81	0.0011	> 100	> 90909
28	0.079	>20	>253	82	0.0026	0.4	151
29	0.015	>20	>1324	83	0.0008	0.4	541
30	0.088	>20	>228	84	0.012	9.3	753
31	0.024	86.8	3630	85	0.002	0.4	208
32	0.403	>100	>248	86	0.010	> 100	> 9803
33	0.042	43.4	1038	87	0.0031	2.2	711
34	0.319	57.8	181	88	0.0027	2.1	767
35	0.103	42.3	409	89	0.0007	0.4	619
36	0.323	>100	>309	90	3.4	30.8	9
37	0.443	33.4	75	91	0.0025	4.9	1976
38	2.449	32.4	13	92	45.0	> 90.0	> 2
39	1.531	>100	>65	93	0.0035	48.1	13743
40	0.253	40.2	158	94	0.0022	11.1	5064
41	1.986	34.2	17	95	0.0006	7.7	12783
42	0.352	35.5	88	96	0.0031	5.8	1885
43	0.603	>100	>165	97	0.032	13.2	415
45	0.010	56.3	5688	98	2.0	13.8	7
46	45.2	>100	>2	99	0.16	59.7	367
47	0.004	>100	>27027	100	0.075	0.8	10
48	44.2	>100	>1	101	0.053	29.5	558
49	0.058	45.2	786	102	0.0082	0.5	63
50	0.518	52.0	100	103	0.022	> 100	4555
51	0.452	>100	>221	104	0.0034	18.6	5476
52	0.001	2.08	2314	105	52.1	< 52.1	< 1
53	0.0006	1.3	2111				

D. Composition examples

The following formulations exemplify typical pharmaceutical compositions suitable for systemic administration to animal and human subjects in accordance with the present invention.

5 "Active ingredient" (A.I.) as used throughout these examples relates to a compound of formula (I) or a pharmaceutically acceptable addition salt thereof.

Example D.1 : film-coated tablets

Preparation of tablet core


10 A mixture of 100 g of the A.I., 570 g lactose and 200 g starch was mixed well and thereafter humidified with a solution of 5 g sodium dodecyl sulfate and 10 g polyvinylpyrrolidone in about 200 ml of water. The wet powder mixture was sieved, dried and sieved again. Then there was added 100 g microcrystalline cellulose and 15 g hydrogenated vegetable oil. The whole was mixed well and compressed into tablets, 15 giving 10.000 tablets, each comprising 10 mg of the active ingredient.

Coating

20 To a solution of 10 g methyl cellulose in 75 ml of denaturated ethanol there was added a solution of 5 g of ethyl cellulose in 150 ml of dichloromethane. Then there were added 75 ml of dichloromethane and 2.5 ml 1,2,3-propanetriol. 10 g of polyethylene glycol was molten and dissolved in 75 ml of dichloromethane. The latter solution was added to the former and then there were added 2.5 g of magnesium octadecanoate, 5 g of polyvinylpyrrolidone and 30 ml of concentrated color suspension and the whole was homogenated. The tablet cores were coated with the thus obtained mixture in a coating apparatus.

Claims.

1. The use of a compound of formula



5 a *N*-oxide, a pharmaceutically acceptable addition salt or a stereochemically isomeric form thereof, wherein
A is CH, CR⁴ or N;
n is 0, 1, 2, 3 or 4;
Q is hydrogen or -NR¹R²;

10 R¹ and R² are each independently selected from hydrogen, hydroxy, C₁₋₁₂alkyl, C₁₋₁₂alkyloxy, C₁₋₁₂alkylcarbonyl, C₁₋₁₂alkyloxycarbonyl, aryl, amino, mono- or di(C₁₋₁₂alkyl)amino, mono- or di(C₁₋₁₂alkyl)aminocarbonyl wherein each of the aforementioned C₁₋₁₂alkyl groups may optionally and each individually be substituted with one or two substituents each independently selected from hydroxy, C₁₋₆alkyloxy, hydroxyC₁₋₆alkyloxy, carboxyl, C₁₋₆alkyloxycarbonyl, cyano, amino, imino, aminocarbonyl, aminocarbonylamino, mono- or di(C₁₋₆alkyl)amino, aryl and Het; or
R¹ and R² taken together may form pyrrolidinyl, piperidinyl, morpholinyl, azido or mono- or di(C₁₋₁₂alkyl)aminoC₁₋₄alkylidene;

15 R³ is hydrogen, aryl, C₁₋₆alkylcarbonyl, C₁₋₆alkyl, C₁₋₆alkyloxycarbonyl, C₁₋₆alkyl substituted with C₁₋₆alkyloxycarbonyl; and
each R⁴ independently is hydroxy, halo, C₁₋₆alkyl, C₁₋₆alkyloxy, cyano, amino- carbonyl, nitro, amino, trihalomethyl, trihalomethoxy or C₁₋₆alkyl substituted with cyano or aminocarbonyl;

20 R⁵ is hydrogen or C₁₋₄alkyl;
L is C₁₋₁₀alkyl, C₃₋₁₀alkenyl, C₃₋₁₀alkynyl, C₃₋₇cycloalkyl, or C₁₋₁₀alkyl substituted with one or two substituents independently selected from C₃₋₇cycloalkyl, indanyl, indolyl and phenyl, wherein said phenyl, indanyl and indolyl may be substituted with one, two, three, four or where possible five substituents each independently selected from halo, hydroxy, C₁₋₆alkyl, C₁₋₆alkyloxy, cyano, aminocarbonyl, C₁₋₆alkyloxycarbonyl, formyl, nitro, amino, trihalomethyl, trihalomethoxy and C₁₋₆alkylcarbonyl; or
L is -X¹-R⁶ or -X²-Alk-R⁷ wherein

R⁶ and R⁷ each independently are phenyl or phenyl substituted with one, two, three, four or five substituents each independently selected from halo, hydroxy, C₁-6alkyl, C₁-6alkyloxy, C₁-6alkylcarbonyl, C₁-6alkyloxycarbonyl, formyl, cyano, aminocarbonyl, nitro, amino, trihalomethoxy and trihalomethyl; and

5 X¹ and X² are each independently -NR³-, -NH-NH-, -N=N-, -O-, -S-, -S(=O)- or -S(=O)₂;

Alk is C₁-4alkanediyl;

aryl is phenyl or phenyl substituted with one, two, three, four or five substituents each independently selected from halo, C₁-6alkyl, C₁-6alkyloxy, cyano, nitro and


10 trifluoromethyl;

Het is an aliphatic or aromatic heterocyclic radical; said aliphatic heterocyclic radical is selected from pyrrolidinyl, piperidinyl, homopiperidinyl, piperazinyl, morpholinyl, tetrahydrofuranyl and tetrahydrothienyl wherein each of said aliphatic heterocyclic radical may optionally be substituted with an oxo group; and said aromatic heterocyclic radical is selected from pyrrolyl, furanyl, thienyl, pyridyl, pyrimidinyl, pyrazinyl and pyridazinyl wherein each of said aromatic heterocyclic radical may optionally be substituted with hydroxy;


15 for the manufacture of a medicine for the treatment of subjects suffering from HIV (Human Immunodeficiency Virus) infection.

20 2. The use of a compound as claimed in claim 1 wherein n is at least 1 and at least one R⁴ is cyano.


3. The use of a compound as claimed in claim 1 or 2 wherein the compound has the formula



25 4. The use of a compound as claimed in any one of claims 1 to 3 wherein the compound has the formula



5. A compound of formula




a *N*-oxide, a pharmaceutically acceptable addition salt or a stereochemically isomeric form thereof, wherein L, Q, R³, R⁴, R⁵ and A are as defined under formula (I), and R^{4'} is halo, C₁₋₆alkyl, cyano, aminocarbonyl, nitro, trihalomethyl, trihalomethoxy or C₁₋₆alkyl substituted with cyano or aminocarbonyl;

5 n' is 0, 1, 2 or 3;

with the proviso that Q and L are other than anilino, 2,4,6-trinitro-anilino, 3-methoxy-anilino, 4-methoxy-anilino, 3,4-dimethoxy-anilino, 3-chloro-4-fluoro-anilino, 4-cyano-anilino, 2-(C₁₋₆alkyl)-anilino, 4-(C₁₋₆alkyl)-anilino, 3-chloro-anilino, 4-bromo-anilino,

10 4-nitro-anilino and 4-chloro-anilino.

6. A compound as claimed in claim 5 wherein the compound has the formula



7. A compound as claimed in claim 6 wherein L and Q are other than anilino, 2,4,6-trinitro-anilino, 4-(C₁₋₆alkyl)-anilino, 4-bromo-anilino, 4-nitro-anilino and 4-chloro-anilino.

8. A compound as claimed in claim 6 or 7 wherein R^{4'} is cyano, aminocarbonyl or C₁₋₆alkyl substituted with cyano or aminocarbonyl.

9. A compound as claimed in any one of claims 5 to 8 wherein L is 2,6-dichlorobenzyl, or L is -X¹-R⁶ wherein X¹ is -NR³- or -S- or -O- and R⁶ is 2,4,6-trichlorophenyl,

20 2,4,6-trimethyl-phenyl, 2,4-dibromo-3,5-dichloro-phenyl, 2,4-dibromo-6-fluoro-phenyl, 2,4-dichloro-6-methyl-phenyl, 2,6-dibromo-4-isopropyl-phenyl, 2,6-dibromo-4-methylphenyl, 2,6-dibromo-4-prop-1-yl-phenyl, 2,6-dichloro-4-cyano-phenyl, 2,6-dichloro-4-trifluoromethoxy-phenyl, 2,6-dichloro-4-trifluoromethyl-phenyl, 2,6-dichloro-phenyl, 2,6-dimethyl-4-(1,1-dimethylethyl)-phenyl,

25 2,6-dimethyl-phenyl, 2-bromo-4-fluoro-6-methyl-phenyl, 2-bromo-6-chloro-4-fluoro-phenyl, 4-bromo-2,6-dimethyl-phenyl, 4-chloro-2,6-dimethyl-phenyl, 4-cyano-2,6-dimethyl-phenyl; or L is -X²-Alk-R⁷ wherein -X²-Alk- is -NH-CH₂- and R⁷ phenyl.

10. A compound as claimed in any one of claims 5 to 9 wherein Q is hydrogen, L is -X¹-R⁶ wherein X¹ is -NH- and R⁶ is 2,4,6-trimethyl-phenyl or 4-cyano-2,6-dimethylphenyl, the NR³(optionally substituted phenyl or pyridyl) moiety represents *p*-cyano-anilino and is in the 2 position of the pyrimidine ring.

5 11. A compound as claimed in any one of claims 5 to 10 wherein R⁴ is halo, cyano, aminocarbonyl or cyanoC₁₋₆alkyl; n is zero, A is CH, R³ is hydrogen; R⁵ is hydrogen or methyl; Q is hydrogen or NHR¹; and L contains phenyl, 2,4,6-trichloro-phenyl, 2,4,6-trimethyl-phenyl, 2,4-dibromo-3,5-dichloro-phenyl, 2,4-dibromo-6-fluoro-phenyl, 2,4-dichloro-6-methyl-phenyl, 2,6-dibromo-4-isopropyl-phenyl,

10 2,6-dibromo-4-methyl-phenyl, 2,6-dibromo-4-prop-1-yl-phenyl, 2,6-dichloro-4-cyano-phenyl, 2,6-dichloro-4-trifluoromethoxy-phenyl, 2,6-dichloro-4-trifluoromethyl-phenyl, 2,6-dichloro-phenyl, 2,6-dimethyl-4-(1,1-dimethylethyl)-phenyl, 2,6-dimethyl-phenyl, 2-bromo-4-fluoro-6-methyl-phenyl, 2-bromo-6-chloro-4-fluoro-phenyl, 4-bromo-2,6-dimethyl-phenyl, 4-chloro-2,6-dimethyl-phenyl, or

15 4-cyano-2,6-dimethyl-phenyl.

12. A compound as claimed in claim 5 wherein the compound is 4-[[4-amino-6-[(2,6-dichlorophenyl)methyl]-2-pyrimidinyl]amino]benzonitrile; 6-[(2,6-dichlorophenyl)methyl]-N2-(4-fluorophenyl)-2,4-pyrimidinediamine; 4-[[4-[(2,4-dichlorophenyl)methyl]-6-[(4-hydroxybutyl)amino]-2-pyrimidinyl]amino]-20 benzonitrile; 4-[[4-[(2,6-dichlorophenyl)methyl]-6-[(3-hydroxypropyl)amino]-2-pyrimidinyl]amino]-benzonitrile; N-[2-[(4-cyanophenyl)amino]-6-[(2,6-dichlorophenyl)methyl]-4-pyrimidinyl]-acetamide; 25 N-[2-[(4-cyanophenyl)amino]-6-[(2,6-dichlorophenyl)methyl]-4-pyrimidinyl]-butanamide; 4-[[2-amino-6-(2,6-dichlorophenoxy)-4-pyrimidinyl]amino]benzonitrile; 4-[[4-[(2,6-dichlorophenyl)methyl]-6-[(2-hydroxy-2-phenylethyl)amino]-2-pyrimidinyl]amino]benzonitrile;

30 4-[[4-[(2,6-dichlorophenyl)methyl]-6-[[3-(2-oxo-1-pyrrolidinyl)propyl]amino]-2-pyrimidinyl]amino]benzonitrile; 4-[[4-[(2,6-dichlorophenyl)methyl]-6-[[2-(2-hydroxyethoxy)ethyl]amino]-2-pyrimidinyl]amino]benzonitrile;

35 4-[[4-[(2,6-dichlorophenyl)methyl]-6-[(2,3-dihydroxypropyl)amino]-2-pyrimidinyl]-amino]benzonitrile;

4-[[4-[(2,6-dichlorophenyl)methyl]-6-(hydroxyamino)-2-pyrimidinyl]amino]-benzonitrile;

4-[[4-[(2-cyanoethyl)amino]-6-[(2,6-dichlorophenyl)methyl]-2-pyrimidinyl]amino]-benzonitrile;

5 4-[[4-[(2,6-dichlorophenyl)methyl]-6-[[2-(1-pyrrolidinyl)ethyl]amino]-2-pyrimidinyl]-amino]benzonitrile;

4-[[4-amino-6-[(2,6-dichlorophenyl)methyl]-5-methyl-2-pyrimidinyl]amino]-benzonitrile;

N2-(4-bromophenyl)-6-[(2,6-dichlorophenyl)methyl]-5-methyl-2,4-pyrimidinediamine;

10 4-[[4-[(2,4,6-trimethylphenyl)amino]-2-pyrimidinyl]amino]benzonitrile;

4-[[2-[(2,4,6-trimethylphenyl)amino]-4-pyrimidinyl]amino]benzonitrile;

4-[[4-[(2,6-dimethylphenyl)amino]-2-pyrimidinyl]amino]benzonitrile;

4-[[4-(2,4,6-trimethylphenoxy)-2-pyrimidinyl]amino]benzonitrile;

4-[[4-[(2,6-dichlorophenyl)thio]-2-pyrimidinyl]amino]benzonitrile;

15 4-[[4-[[2,6-dibromo-4-(1-methylethyl)phenyl]amino]-2-pyrimidinyl]amino]-benzonitrile;

4-[[4-[[2,6-dichloro-4-(trifluoromethyl)phenyl]amino]-2-pyrimidinyl]amino]-benzonitrile;

4-[[4-[(2,4-dichloro-6-methylphenyl)amino]-2-pyrimidinyl]amino]benzonitrile;

20 4-[[2-[(cyanophenyl)amino]-4-pyrimidinyl]amino]-3,5-dimethylbenzonitrile;

4-[[4-[(2,4-dibromo-6-fluorophenyl)amino]-2-pyrimidinyl]amino]benzonitrile;

4-[[4-amino-6-[(2,6-dichlorophenyl)methyl]-5-methyl-2-pyrimidinyl]amino]-benzeneacetonitrile;

4-[[4-[methyl(2,4,6-trimethylphenyl)amino]-2-pyrimidinyl]amino]benzonitrile;

25 4-[[4-[(2,4,6-trichlorophenyl)amino]-2-pyrimidinyl]amino]benzonitrile ;

4-[[4-[(2,4,6-trimethylphenyl)thio]-2-pyrimidinyl]amino]benzonitrile;

4-[[4-[(2,4,6-trimethylphenyl)amino]-2-pyrimidinyl]amino]benzonitrile;

4-[[4-amino-6-[(2,4,6-trimethylphenyl)amino]-2-pyrimidinyl]amino]benzonitrile;

4-[[2-amino-6-[(2,4,6-trimethylphenyl)amino]-4-pyrimidinyl]amino]benzonitrile;

30 4-[[4-(2-bromo-4-chloro-6-methylphenoxy)-2-pyrimidinyl]amino]benzonitrile;

4-[[4-[(4-chloro-2,6-dimethylphenyl)amino]-2-pyrimidinyl]amino]benzonitrile;

3,5-dichloro-4-[[2-[(4-cyanophenyl)amino]-4-pyrimidinyl]amino]benzonitrile;

4-[[4-[[2,6-dichloro-4-(trifluoromethoxy)phenyl]amino]-2-pyrimidinyl]amino]-benzonitrile;

35 4-[[4-[(2,4-dibromo-3,6-dichlorophenyl)amino]-2-pyrimidinyl]amino]benzonitrile;

4-[[4-[(2,6-dibromo-4-propylphenyl)amino]-2-pyrimidinyl]amino]benzonitrile;

4-[[4-[(2,4,6-trimethylphenyl)amino]-2-pyrimidinyl]amino]benzamide;

4-[(4-[(4-(1,1-dimethylethyl)-2,6-dimethylphenyl)amino]-2-pyrimidinyl]amino]-benzonitrile;

4-[[2-[(4-cyanophenyl)amino]-4-pyrimidinyl]oxy]-3,5-dimethylbenzonitrile;

4-[[4-[(4-chloro-2,6-dimethylphenyl)amino]-5-methyl-2-pyrimidinyl]amino]-benzonitrile;

5 4-[[2-[(4-cyanophenyl)amino]-5-methyl-4-pyrimidinyl]amino]-3,5-dimethyl-benzonitrile;

4-[[4-[(4-(1,1-dimethylethyl)-2,6-dimethylphenyl)amino]-5-methyl-2-pyrimidinyl]-amino]benzonitrile;

10 4-[[4-[(4-bromo-2,6-dimethylphenyl)amino]-5-methyl-2-pyrimidinyl]amino]-benzonitrile;

4-[[5-methyl-4-[(2,4,6-trimethylphenyl)thio]-2-pyrimidinyl]amino]benzonitrile;

4-[[4-[(2,6-dibromo-4-propylphenyl)amino]-5-methyl-2-pyrimidinyl]amino]-benzonitrile;

15 4-[[4-[(2,4,6-trimethylphenyl)amino]-2-pyrimidinyl]amino]benzamide, *N*3-oxide; *N*2-(4-chlorophenyl)-*N*4-(2,4,6-trimethylphenyl)-2,4-pyrimidinediamine;

4-[[4-[(2,6-dibromo-4-(1-methylethyl)phenyl)amino]-5-methyl-2-pyrimidinyl]amino]-benzonitrile;

4-[[2-[(4-cyanophenyl)amino]-5-methyl-4-pyrimidinyl]amino]-3,5-dimethyl-

20 benzonitrile;


4-[[4-[(phenylmethyl)amino]-2-pyrimidinyl]amino]benzonitrile;

a *N*-oxide, a pharmaceutically acceptable addition salt or a stereochemically isomeric form thereof.

13. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a therapeutically active amount of a compound as defined in any one of claims 25 5 to 12.


14. A process for preparing a pharmaceutical composition as defined in claim 13 characterized in that a therapeutically effective amount of a compound as defined in any one of claims 5 to 12 is intimately mixed with a pharmaceutically acceptable carrier.

30 15. A process for preparing a compound as defined in claim 5, characterized by a) reacting an intermediate of formula (II-A) wherein W^1 is a suitable leaving group with an amino derivative of formula (III) optionally in a solvent under a reaction-inert atmosphere, and optionally in the presence of an acid




wherein Q , R^3 , R^4 , $R^{4'}$, R^5 , A , n' and L are as defined in claim 5;

5 b) reacting an intermediate of formula (II-B) wherein W^1 is a suitable leaving group with an amino derivative of formula (VI) optionally in a solvent under a reaction-inert atmosphere, and optionally in the presence of an acid



10 c) reacting an intermediate $H-X^1-R^6$ with an intermediate of formula (II-C) in a suitable solvent optionally in the presence of a suitable acid or base; thus obtaining compounds of formula (I') wherein L is $-X^1-R^6$, said compounds being represented by formula (I'-c).
 10



15 or if desired, converting compounds of formula (I') into each other following art-known transformations, and further, if desired, converting the compounds of formula (I'), into a therapeutically active non-toxic acid addition salt by treatment with an acid, or into a therapeutically active non-toxic base addition salt by treatment with a base, or conversely, converting the acid addition salt form into the free base by treatment with alkali, or converting the base addition salt into the free acid by treatment with acid; and, if desired, preparing stereochemically isomeric forms or N -oxides thereof..
 20

16. A compound as claimed in claim 5 for use as a medicine.

17. The combination of a compound of formula (I) as defined in claim 1 and another antiretroviral compound.

18. The combination of a compound of formula (I') as defined in claim 5 and another antiretroviral compound.

19. A combination as claimed in claim 17 or 18 for use as a medicine.


20. A product containing (a) a compound of formula (I) as defined in claim 1, and (b) another antiretroviral compound, as a combined preparation for simultaneous, separate or sequential use in anti-HIV treatment.

21. A product containing (a) a compound of formula (I') as defined in claim 5, and (b) another antiretroviral compound, as a combined preparation for simultaneous, separate or sequential use in anti-HIV treatment.

22. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and as active ingredients (a) a compound of formula (I) as defined in claim 1, and (b) another antiretroviral compound.

23. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and as active ingredients (a) a compound of formula (I') as defined in claim 5, and (b) another antiretroviral compound.

25 24. A compound of formula (II'-B)



wherein R³, R⁴, R^{4'}, n', A and L are as defined in claim 5 and W¹ is a halogen.

INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 99/02043

A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 C07D239/50 C07D239/48 C07D239/46 C07D239/42 C07D401/12
A61K31/505

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C07D A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	WO 91 18887 A (SMITH KLINE) 12 December 1991 (1991-12-12) cited in the application claims 1-3; examples 1-38 ---	1-4, 13-23
Y	EP 0 588 762 A (CIBA-GEIGY) 23 March 1994 (1994-03-23) page 3, line 39 - line 42; claims ---	1-4, 13-23
A	WO 95 10506 A (DU PONT MERCK) 20 April 1995 (1995-04-20) page 1 - page 13; claims claims; examples 4,7,32; table 1 ---	1-4, 13-23
X	claims; examples 4,7,32; table 1 ---	5,6,13, 16,24
A	EP 0 270 111 A (KUMIAI) 8 June 1988 (1988-06-08) the whole document ---	5,24
		-/-

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

[°] Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

Date of mailing of the international search report

14 July 1999

29/07/1999

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Francois, J

INTERNATIONAL SEARCH REPORT

International Application No	PCT/EP 99/02043
------------------------------	-----------------

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	<p>DOLLY GOSH: "2,4-BIS(ARYLAMINO)-5-METHYLPYRIMIDINES AS ANTIMICROBIAL AGENTS." JOURNAL OF MEDICINAL CHEMISTRY., vol. 10, September 1969 (1969-09), pages 974-975, XP002109182 AMERICAN CHEMICAL SOCIETY. WASHINGTON., US ISSN: 0022-2623 page 974 - page 975</p> <p>---</p> <p>CHEN CHEN ET AL.: "DESIGN AND SYNTHESIS OF A SERIE OF NON-PEPTIDE HIGH AFFINITY HUMAN CORTICOTROPIN-RELEASING FACTOR" JOURNAL OF MEDICINAL CHEMISTRY., vol. 39, 1996, pages 4358-4360, XP002109183 AMERICAN CHEMICAL SOCIETY. WASHINGTON., US ISSN: 0022-2623 page 4358 - page 4359</p> <p>---</p> <p>CHEMICAL ABSTRACTS, vol. 95, no. 11, 1981 Columbus, Ohio, US; abstract no. 97712f, D.GOSH: "2,4-BIS(ARYLAMINO)-6-METHYLPYRIMIDINES AS ANTIMICROBIAL AGENTS." page 648; XP002109184 abstract & J.INDIAN CHEM. SOC., vol. 58, no. 5, 1981, pages 512-513, INDIA</p> <p>-----</p>	1-6, 13-23
A		1-6, 13-23
A		1-6, 13-23

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP 99/02043

Patent document cited in search report		Publication date		Patent family member(s)		Publication date
WO 9118887	A	12-12-1991	AU	7971691 A		31-12-1991
EP 588762	A	23-03-1994	JP	6184116 A		05-07-1994
			US	5516775 A		14-05-1996
WO 9510506	A	20-04-1995	AU	692484 B		11-06-1998
			AU	8012294 A		04-05-1995
			BR	9407799 A		06-05-1997
			CA	2174080 A		20-04-1995
			CN	1142817 A		12-02-1997
			CZ	9601014 A		13-11-1996
			EP	0723533 A		31-07-1996
			FI	961599 A		07-06-1996
			HR	940664 A		31-12-1996
			HU	74464 A		30-12-1996
			JP	9504520 T		06-05-1997
			NO	961425 A		12-06-1996
			NZ	274978 A		27-04-1998
			PL	313973 A		05-08-1996
			SK	47096 A		01-10-1996
			ZA	9407921 A		11-04-1996
EP 270111	A	08-06-1988	JP	2065338 C		24-06-1996
			JP	7084445 B		13-09-1995
			JP	63141971 A		14-06-1988
			US	4992438 A		12-02-1991